User login
Expert offers caveats to perioperative antirheumatic drug guideline
The latest guideline for perioperative management of antirheumatic medication in patients undergoing total hip (THA) and total knee arthroplasty (TKA) offers recommendations based on the latest evidence, but many of those recommendations are based on a low level of evidence, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.
Martin Bergman, MD, clinical professor of medicine at Drexel University, Philadelphia, said the development of the American College of Rheumatology/American Association of Hip and Knee Surgeons guideline was necessary because there was a lack of consensus on when to stop treatments prior to patients with rheumatologic disease undergoing THA and TKA, and when it was appropriate to restart those treatments.
“We all were having the same problem, and I think everybody recognized that just stopping medicines forever didn’t make sense, but maybe continuing medicines also didn’t make sense,” Dr. Bergman said.
While the 2017 ACR/AAHKS perioperative management guideline contained good recommendations, the “explosion” of new medications in rheumatology made it necessary to update the guideline with the latest data on new medications such as immunosuppressants.
2022 guideline recommendations
In the 2022 guideline, which covers disease-modifying treatments taken by patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis, the authors reaffirmed their recommendations to continue methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, and apremilast through total joint arthroplasty.
Where the 2022 guideline differs from the 2017 guideline is in which biologics are covered and under what circumstances they should be withheld and restarted around surgery. The 2022 guideline includes recommendations for abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, rituximab, secukinumab, tocilizumab, and ustekinumab. Each biologic has its own recommended stop and restart times based around the dosing interval and respective method of administration. Dr. Bergman said a general rule with biologics under the new guideline is that the timing of surgery should occur approximately 1 week after the first missed dose of the medication. The only biologic that does not follow this pattern is rituximab, where surgery should be planned for 1 month after the last missed dose.
Dr. Bergman noted that how the guidelines handle interval dosing with infliximab may present a problem. The guideline provides recommendations for patients receiving infliximab every 4 weeks, every 6 weeks, and every 8 weeks. However, Dr. Bergman said this can create a scenario where a patient receiving infliximab at a dose of 3 mg/kg every 8 weeks has surgery at 9 weeks, a patient receiving 5 mg/kg every 6 weeks has surgery at 7 weeks, and a patient receiving 10 mg/kg every 4 weeks has surgery at 5 weeks. “There is some intellectual problem with it,” he said.
Another change from the 2017 guideline is how long to wait for surgery after stopping Janus kinase inhibitors. While the 2017 guideline recommended withholding JAK inhibitors 7 days before surgery, the 2022 guideline lowered that waiting period to 3 days, Dr. Bergman explained.
Concerning use of steroids around THA and TKA surgery, “the days of stress steroid dosing are done,” Dr. Bergman said. “You don’t have to stress dose them. You just follow them, and you keep them on their steroid dose.”
The new guideline recommends restarting therapy once the wound is healed and there is no physical evidence of infection at approximately 2 weeks. “There’s no data to support this,” he said, and his concern is that patients who have stopped a tumor necrosis factor inhibitor may flare if they don’t restart their medication.
While the guideline also covered recommendations for systemic lupus erythematosus, they are “very similar” to the recommendations for inflammatory arthritis, Dr. Bergman noted. “If you have somebody who is not very sick, you stop the medications,” he said, “but try to stop anything else about a week before the surgery. If they’re sick, you basically have to keep them on their medications.”
Caveats in guideline
The recommendations in the 2022 guideline come with a number of caveats, Dr. Bergman noted. For instance, the authors acknowledged limitations in the guideline regarding providing recommendations for only THA and TKA, the “paucity of evidence” around direct infection risk resulting from medications in the perioperative period for THA and TKA, the nonseparation of biologics when assessing infection risk, and the use of dosing interval as a metric for stopping the drug without considering the drug’s half-life.
A “crucial caveat,” Dr. Bergman said, was that the guideline focused on infection risk based on a statement from a panel of patients prior to the development of the 2017 guideline, which “stated very clearly any risk of infection, while rare, was more significant to them than the possibility of postoperative flares, despite flares being reported in over 60% of patients after surgery.
“For the patients, the paramount question was infection, infection, infection, infection. That’s all they cared about, and that is the basis behind a lot of the decision-making here,” Dr. Bergman said.
Another caveat came from a communication Dr. Bergman received from one of the panel members. The panel member noted there were no conclusions or recommendations provided in the guideline for how to manage perioperative flares, such as restarting a corticosteroid or biologic agent. “There was a lot of discussion about what to do with steroids if patients flare, or what to do with [other] medications if they flare, and they just couldn’t come to a consensus,” Dr. Bergman said. “It’s just not discussed.”
Dr. Bergman said he is “somewhat critical” of the ACR/AAHKS guideline, but noted it is an “ambitious project” given the lack of evidence for the recommendations. “The alternative was stop the medications forever and having people really flare, or at least try to get some semblance of rationality behind what we’re going to do,” he said.
Response from attendees
Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, took issue with the new recommendations surrounding stopping infliximab. When giving a patient infliximab every 8 weeks at 3 mg/kg, “you’re giving [it] at the nadir of the drug,” he said.
Rather than drug half-life, “it’s about inflammation,” he emphasized. “Inflammation is dominant in causing infection. It drives risk more than anything. The worst thing you can do is wash someone out.
“If you’re going beyond 8 weeks on infliximab, you’re getting closer to washing them out,” he pointed out. “I think it’s a really bad idea.”
Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at Hospital for Special Surgery, both in New York, explained that the guideline is not standard of care, which would be subject to malpractice if not implemented properly.
“When you have guidelines, you follow them unless there are clinical situations which would necessitate another approach to the patient,” he said. “Professional institutions and associations will never put forth rules, they will put forth guidelines so you have the opportunity to deviate from them when the appropriate clinical situation dictates.”
Dr. Bergman reported being a speaker and consultant for AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and Regeneron; he holds stock in Johnson & Johnson and Merck.
The latest guideline for perioperative management of antirheumatic medication in patients undergoing total hip (THA) and total knee arthroplasty (TKA) offers recommendations based on the latest evidence, but many of those recommendations are based on a low level of evidence, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.
Martin Bergman, MD, clinical professor of medicine at Drexel University, Philadelphia, said the development of the American College of Rheumatology/American Association of Hip and Knee Surgeons guideline was necessary because there was a lack of consensus on when to stop treatments prior to patients with rheumatologic disease undergoing THA and TKA, and when it was appropriate to restart those treatments.
“We all were having the same problem, and I think everybody recognized that just stopping medicines forever didn’t make sense, but maybe continuing medicines also didn’t make sense,” Dr. Bergman said.
While the 2017 ACR/AAHKS perioperative management guideline contained good recommendations, the “explosion” of new medications in rheumatology made it necessary to update the guideline with the latest data on new medications such as immunosuppressants.
2022 guideline recommendations
In the 2022 guideline, which covers disease-modifying treatments taken by patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis, the authors reaffirmed their recommendations to continue methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, and apremilast through total joint arthroplasty.
Where the 2022 guideline differs from the 2017 guideline is in which biologics are covered and under what circumstances they should be withheld and restarted around surgery. The 2022 guideline includes recommendations for abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, rituximab, secukinumab, tocilizumab, and ustekinumab. Each biologic has its own recommended stop and restart times based around the dosing interval and respective method of administration. Dr. Bergman said a general rule with biologics under the new guideline is that the timing of surgery should occur approximately 1 week after the first missed dose of the medication. The only biologic that does not follow this pattern is rituximab, where surgery should be planned for 1 month after the last missed dose.
Dr. Bergman noted that how the guidelines handle interval dosing with infliximab may present a problem. The guideline provides recommendations for patients receiving infliximab every 4 weeks, every 6 weeks, and every 8 weeks. However, Dr. Bergman said this can create a scenario where a patient receiving infliximab at a dose of 3 mg/kg every 8 weeks has surgery at 9 weeks, a patient receiving 5 mg/kg every 6 weeks has surgery at 7 weeks, and a patient receiving 10 mg/kg every 4 weeks has surgery at 5 weeks. “There is some intellectual problem with it,” he said.
Another change from the 2017 guideline is how long to wait for surgery after stopping Janus kinase inhibitors. While the 2017 guideline recommended withholding JAK inhibitors 7 days before surgery, the 2022 guideline lowered that waiting period to 3 days, Dr. Bergman explained.
Concerning use of steroids around THA and TKA surgery, “the days of stress steroid dosing are done,” Dr. Bergman said. “You don’t have to stress dose them. You just follow them, and you keep them on their steroid dose.”
The new guideline recommends restarting therapy once the wound is healed and there is no physical evidence of infection at approximately 2 weeks. “There’s no data to support this,” he said, and his concern is that patients who have stopped a tumor necrosis factor inhibitor may flare if they don’t restart their medication.
While the guideline also covered recommendations for systemic lupus erythematosus, they are “very similar” to the recommendations for inflammatory arthritis, Dr. Bergman noted. “If you have somebody who is not very sick, you stop the medications,” he said, “but try to stop anything else about a week before the surgery. If they’re sick, you basically have to keep them on their medications.”
Caveats in guideline
The recommendations in the 2022 guideline come with a number of caveats, Dr. Bergman noted. For instance, the authors acknowledged limitations in the guideline regarding providing recommendations for only THA and TKA, the “paucity of evidence” around direct infection risk resulting from medications in the perioperative period for THA and TKA, the nonseparation of biologics when assessing infection risk, and the use of dosing interval as a metric for stopping the drug without considering the drug’s half-life.
A “crucial caveat,” Dr. Bergman said, was that the guideline focused on infection risk based on a statement from a panel of patients prior to the development of the 2017 guideline, which “stated very clearly any risk of infection, while rare, was more significant to them than the possibility of postoperative flares, despite flares being reported in over 60% of patients after surgery.
“For the patients, the paramount question was infection, infection, infection, infection. That’s all they cared about, and that is the basis behind a lot of the decision-making here,” Dr. Bergman said.
Another caveat came from a communication Dr. Bergman received from one of the panel members. The panel member noted there were no conclusions or recommendations provided in the guideline for how to manage perioperative flares, such as restarting a corticosteroid or biologic agent. “There was a lot of discussion about what to do with steroids if patients flare, or what to do with [other] medications if they flare, and they just couldn’t come to a consensus,” Dr. Bergman said. “It’s just not discussed.”
Dr. Bergman said he is “somewhat critical” of the ACR/AAHKS guideline, but noted it is an “ambitious project” given the lack of evidence for the recommendations. “The alternative was stop the medications forever and having people really flare, or at least try to get some semblance of rationality behind what we’re going to do,” he said.
Response from attendees
Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, took issue with the new recommendations surrounding stopping infliximab. When giving a patient infliximab every 8 weeks at 3 mg/kg, “you’re giving [it] at the nadir of the drug,” he said.
Rather than drug half-life, “it’s about inflammation,” he emphasized. “Inflammation is dominant in causing infection. It drives risk more than anything. The worst thing you can do is wash someone out.
“If you’re going beyond 8 weeks on infliximab, you’re getting closer to washing them out,” he pointed out. “I think it’s a really bad idea.”
Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at Hospital for Special Surgery, both in New York, explained that the guideline is not standard of care, which would be subject to malpractice if not implemented properly.
“When you have guidelines, you follow them unless there are clinical situations which would necessitate another approach to the patient,” he said. “Professional institutions and associations will never put forth rules, they will put forth guidelines so you have the opportunity to deviate from them when the appropriate clinical situation dictates.”
Dr. Bergman reported being a speaker and consultant for AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and Regeneron; he holds stock in Johnson & Johnson and Merck.
The latest guideline for perioperative management of antirheumatic medication in patients undergoing total hip (THA) and total knee arthroplasty (TKA) offers recommendations based on the latest evidence, but many of those recommendations are based on a low level of evidence, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.
Martin Bergman, MD, clinical professor of medicine at Drexel University, Philadelphia, said the development of the American College of Rheumatology/American Association of Hip and Knee Surgeons guideline was necessary because there was a lack of consensus on when to stop treatments prior to patients with rheumatologic disease undergoing THA and TKA, and when it was appropriate to restart those treatments.
“We all were having the same problem, and I think everybody recognized that just stopping medicines forever didn’t make sense, but maybe continuing medicines also didn’t make sense,” Dr. Bergman said.
While the 2017 ACR/AAHKS perioperative management guideline contained good recommendations, the “explosion” of new medications in rheumatology made it necessary to update the guideline with the latest data on new medications such as immunosuppressants.
2022 guideline recommendations
In the 2022 guideline, which covers disease-modifying treatments taken by patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis, the authors reaffirmed their recommendations to continue methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, and apremilast through total joint arthroplasty.
Where the 2022 guideline differs from the 2017 guideline is in which biologics are covered and under what circumstances they should be withheld and restarted around surgery. The 2022 guideline includes recommendations for abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, rituximab, secukinumab, tocilizumab, and ustekinumab. Each biologic has its own recommended stop and restart times based around the dosing interval and respective method of administration. Dr. Bergman said a general rule with biologics under the new guideline is that the timing of surgery should occur approximately 1 week after the first missed dose of the medication. The only biologic that does not follow this pattern is rituximab, where surgery should be planned for 1 month after the last missed dose.
Dr. Bergman noted that how the guidelines handle interval dosing with infliximab may present a problem. The guideline provides recommendations for patients receiving infliximab every 4 weeks, every 6 weeks, and every 8 weeks. However, Dr. Bergman said this can create a scenario where a patient receiving infliximab at a dose of 3 mg/kg every 8 weeks has surgery at 9 weeks, a patient receiving 5 mg/kg every 6 weeks has surgery at 7 weeks, and a patient receiving 10 mg/kg every 4 weeks has surgery at 5 weeks. “There is some intellectual problem with it,” he said.
Another change from the 2017 guideline is how long to wait for surgery after stopping Janus kinase inhibitors. While the 2017 guideline recommended withholding JAK inhibitors 7 days before surgery, the 2022 guideline lowered that waiting period to 3 days, Dr. Bergman explained.
Concerning use of steroids around THA and TKA surgery, “the days of stress steroid dosing are done,” Dr. Bergman said. “You don’t have to stress dose them. You just follow them, and you keep them on their steroid dose.”
The new guideline recommends restarting therapy once the wound is healed and there is no physical evidence of infection at approximately 2 weeks. “There’s no data to support this,” he said, and his concern is that patients who have stopped a tumor necrosis factor inhibitor may flare if they don’t restart their medication.
While the guideline also covered recommendations for systemic lupus erythematosus, they are “very similar” to the recommendations for inflammatory arthritis, Dr. Bergman noted. “If you have somebody who is not very sick, you stop the medications,” he said, “but try to stop anything else about a week before the surgery. If they’re sick, you basically have to keep them on their medications.”
Caveats in guideline
The recommendations in the 2022 guideline come with a number of caveats, Dr. Bergman noted. For instance, the authors acknowledged limitations in the guideline regarding providing recommendations for only THA and TKA, the “paucity of evidence” around direct infection risk resulting from medications in the perioperative period for THA and TKA, the nonseparation of biologics when assessing infection risk, and the use of dosing interval as a metric for stopping the drug without considering the drug’s half-life.
A “crucial caveat,” Dr. Bergman said, was that the guideline focused on infection risk based on a statement from a panel of patients prior to the development of the 2017 guideline, which “stated very clearly any risk of infection, while rare, was more significant to them than the possibility of postoperative flares, despite flares being reported in over 60% of patients after surgery.
“For the patients, the paramount question was infection, infection, infection, infection. That’s all they cared about, and that is the basis behind a lot of the decision-making here,” Dr. Bergman said.
Another caveat came from a communication Dr. Bergman received from one of the panel members. The panel member noted there were no conclusions or recommendations provided in the guideline for how to manage perioperative flares, such as restarting a corticosteroid or biologic agent. “There was a lot of discussion about what to do with steroids if patients flare, or what to do with [other] medications if they flare, and they just couldn’t come to a consensus,” Dr. Bergman said. “It’s just not discussed.”
Dr. Bergman said he is “somewhat critical” of the ACR/AAHKS guideline, but noted it is an “ambitious project” given the lack of evidence for the recommendations. “The alternative was stop the medications forever and having people really flare, or at least try to get some semblance of rationality behind what we’re going to do,” he said.
Response from attendees
Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, took issue with the new recommendations surrounding stopping infliximab. When giving a patient infliximab every 8 weeks at 3 mg/kg, “you’re giving [it] at the nadir of the drug,” he said.
Rather than drug half-life, “it’s about inflammation,” he emphasized. “Inflammation is dominant in causing infection. It drives risk more than anything. The worst thing you can do is wash someone out.
“If you’re going beyond 8 weeks on infliximab, you’re getting closer to washing them out,” he pointed out. “I think it’s a really bad idea.”
Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at Hospital for Special Surgery, both in New York, explained that the guideline is not standard of care, which would be subject to malpractice if not implemented properly.
“When you have guidelines, you follow them unless there are clinical situations which would necessitate another approach to the patient,” he said. “Professional institutions and associations will never put forth rules, they will put forth guidelines so you have the opportunity to deviate from them when the appropriate clinical situation dictates.”
Dr. Bergman reported being a speaker and consultant for AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and Regeneron; he holds stock in Johnson & Johnson and Merck.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>162290</fileName> <TBEID>0C0487FB.SIG</TBEID> <TBUniqueIdentifier>MD_0C0487FB</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname>RWCS 23 Bergman THA TKA gls</storyname> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20230223T094938</QCDate> <firstPublished>20230223T093441</firstPublished> <LastPublished>20230223T093441</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20230223T093441</CMSDate> <articleSource>FROM RWCS 2023</articleSource> <facebookInfo/> <meetingNumber>4660-23</meetingNumber> <byline>Jeff Craven</byline> <bylineText>JEFF CRAVEN</bylineText> <bylineFull>JEFF CRAVEN</bylineFull> <bylineTitleText>MDedge News</bylineTitleText> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>The latest guideline for perioperative management of antirheumatic medication in patients undergoing total hip (THA) and total knee arthroplasty (TKA) offers re</metaDescription> <articlePDF/> <teaserImage/> <teaser>Experts say the 2022 ACR/AAHKS guideline on perioperative management of antirheumatic medications in total hip and total knee arthroplasty have a number of caveats that limit the usefulness of the recommendations.</teaser> <title>Expert offers caveats to perioperative antirheumatic drug guideline</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>rn</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>mdsurg</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> <journalTitle/> <journalFullTitle/> <copyrightStatement>2018 Frontline Medical Communications Inc.,</copyrightStatement> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">26</term> <term>52226</term> <term>21</term> </publications> <sections> <term canonical="true">53</term> <term>75</term> <term>39313</term> </sections> <topics> <term canonical="true">289</term> <term>299</term> <term>282</term> <term>183</term> <term>264</term> <term>290</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Expert offers caveats to perioperative antirheumatic drug guideline</title> <deck/> </itemMeta> <itemContent> <p>The latest guideline for perioperative management of antirheumatic medication in patients undergoing total hip (THA) and total knee arthroplasty (TKA) offers recommendations based on the latest evidence, but many of those recommendations are based on a low level of evidence, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.</p> <p>Martin Bergman, MD, clinical professor of medicine at Drexel University, Philadelphia, said the development of the <span class="Hyperlink"><a href="https://www.rheumatology.org/Portals/0/Files/Perioperative-Management-Guideline.pdf">American College of Rheumatology/American Association of Hip and Knee Surgeons guideline</a></span> was necessary because there was a lack of consensus on when to stop treatments prior to patients with rheumatologic disease undergoing THA and TKA, and when it was appropriate to restart those treatments.<br/><br/>“We all were having the same problem, and I think everybody recognized that just stopping medicines forever didn’t make sense, but maybe continuing medicines also didn’t make sense,” Dr. Bergman said.<br/><br/>While the <span class="Hyperlink"><a href="https://www.rheumatology.org/Portals/0/Files/ACR-AAHKS-Perioperative-Management-Guideline.pdf">2017 ACR/AAHKS perioperative management guideline</a></span> contained good recommendations, the “explosion” of new medications in rheumatology made it necessary to update the guideline with the latest data on new medications such as immunosuppressants.<br/><br/></p> <h2>2022 guideline recommendations</h2> <p>In the 2022 guideline, which covers disease-modifying treatments taken by patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis, the authors reaffirmed their recommendations to continue methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, and apremilast through total joint arthroplasty. </p> <p>Where the 2022 guideline differs from the 2017 guideline is in which biologics are covered and under what circumstances they should be withheld and restarted around surgery. The 2022 guideline includes recommendations for abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, rituximab, secukinumab, tocilizumab, and ustekinumab. Each biologic has its own recommended stop and restart times based around the dosing interval and respective method of administration. Dr. Bergman said a general rule with biologics under the new guideline is that the timing of surgery should occur approximately 1 week after the first missed dose of the medication. The only biologic that does not follow this pattern is rituximab, where surgery should be planned for 1 month after the last missed dose. <br/><br/>Dr. Bergman noted that how the guidelines handle interval dosing with infliximab may present a problem. The guideline provides recommendations for patients receiving infliximab every 4 weeks, every 6 weeks, and every 8 weeks. However, Dr. Bergman said this can create a scenario where a patient receiving infliximab at a dose of 3 mg/kg every 8 weeks has surgery at 9 weeks, a patient receiving 5 mg/kg every 6 weeks has surgery at 7 weeks, and a patient receiving 10 mg/kg every 4 weeks has surgery at 5 weeks. “There is some intellectual problem with it,” he said.<br/><br/>Another change from the 2017 guideline is how long to wait for surgery after stopping Janus kinase inhibitors. While the 2017 guideline recommended withholding JAK inhibitors 7 days before surgery, the 2022 guideline lowered that waiting period to 3 days, Dr. Bergman explained.<br/><br/>Concerning use of steroids around THA and TKA surgery, “the days of stress steroid dosing are done,” Dr. Bergman said. “You don’t have to stress dose them. You just follow them, and you keep them on their steroid dose.”<br/><br/>The new guideline recommends restarting therapy once the wound is healed and there is no physical evidence of infection at approximately 2 weeks. “There’s no data to support this,” he said, and his concern is that patients who have stopped a tumor necrosis factor inhibitor may flare if they don’t restart their medication.<br/><br/>While the guideline also covered recommendations for systemic lupus erythematosus, they are “very similar” to the recommendations for inflammatory arthritis, Dr. Bergman noted. “If you have somebody who is not very sick, you stop the medications,” he said, “but try to stop anything else about a week before the surgery. If they’re sick, you basically have to keep them on their medications.”<br/><br/></p> <h2>Caveats in guideline</h2> <p>The recommendations in the 2022 guideline come with a number of caveats, Dr. Bergman noted. For instance, the authors acknowledged limitations in the guideline regarding providing recommendations for only THA and TKA, the “paucity of evidence” around direct infection risk resulting from medications in the perioperative period for THA and TKA, the nonseparation of biologics when assessing infection risk, and the use of dosing interval as a metric for stopping the drug without considering the drug’s half-life.</p> <p>A “crucial caveat,” Dr. Bergman said, was that the guideline focused on infection risk based on a statement from a panel of patients prior to the development of the 2017 guideline, which “stated very clearly any risk of infection, while rare, was more significant to them than the possibility of postoperative flares, despite flares being reported in over 60% of patients after surgery.<br/><br/>“For the patients, the paramount question was infection, infection, infection, infection. That’s all they cared about, and that is the basis behind a lot of the decision-making here,” Dr. Bergman said.<br/><br/>Another caveat came from a communication Dr. Bergman received from one of the panel members. The panel member noted there were no conclusions or recommendations provided in the guideline for how to manage perioperative flares, such as restarting a corticosteroid or biologic agent. “There was a lot of discussion about what to do with steroids if patients flare, or what to do with [other] medications if they flare, and they just couldn’t come to a consensus,” Dr. Bergman said. “It’s just not discussed.”<br/><br/>Dr. Bergman said he is “somewhat critical” of the ACR/AAHKS guideline, but noted it is an “ambitious project” given the lack of evidence for the recommendations. “The alternative was stop the medications forever and having people really flare, or at least try to get some semblance of rationality behind what we’re going to do,” he said.<br/><br/></p> <h2>Response from attendees</h2> <p>Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, took issue with the new recommendations surrounding stopping infliximab. When giving a patient infliximab every 8 weeks at 3 mg/kg, “you’re giving [it] at the nadir of the drug,” he said. </p> <p>Rather than drug half-life, “it’s about inflammation,” he emphasized. “Inflammation is dominant in causing infection. It drives risk more than anything. The worst thing you can do is wash someone out.<br/><br/>“If you’re going beyond 8 weeks on infliximab, you’re getting closer to washing them out,” he pointed out. “I think it’s a really bad idea.”<br/><br/>Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at Hospital for Special Surgery, both in New York, explained that the guideline is not standard of care, which would be subject to malpractice if not implemented properly.<br/><br/>“When you have guidelines, you follow them unless there are clinical situations which would necessitate another approach to the patient,” he said. “Professional institutions and associations will never put forth rules, they will put forth guidelines so you have the opportunity to deviate from them when the appropriate clinical situation dictates.”<br/><br/>Dr. Bergman reported being a speaker and consultant for AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and Regeneron; he holds stock in Johnson & Johnson and Merck.</p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>
FROM RWCS 2023
Adaptations to education, training vital to alleviating rheumatologist shortage
To address the growing workforce shortage in rheumatology, medical educators will have to adapt and learn how to train a new generation of rheumatologists, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.
Anisha B. Dua, MD, an associate professor of rheumatology at Northwestern University, Chicago, told attendees she is “heavily invested in the training of our future rheumatologists” and strives to help them “operate at the top of the level across the spectrum.”
“They’re carrying forward our field,” Dr. Dua said. “We need to propagate our field and we need them to go out and serve and continue to make rheumatology awesome.”
The American College of Rheumatology’s 2015 workforce study estimates that by 2030, there will be a shortage of more than 4,000 rheumatologists in the United States.
Rheumatology may have inadvertently created the problem through rheumatologists diagnosing disease earlier and prescribing better treatments, with patients subsequently living longer with disease, she noted. Compounding the problem is an increasing number of rheumatologists looking to retire over the next decade and the continued need for care in rural areas where there are few practicing rheumatologists.
Interest in rheumatology is increasing
The good news is there is increasing interest in the field. “This has really shifted, I would say, from about 10 years ago when I was looking at fellowships,” Dr. Dua said. “It’s not really an interest problem. But the issue is that the training programs and slots don’t necessarily exist to fill the gap of the people who are leaving the field.”
The key to bringing more people into rheumatology is to understand how Millennials and Generation Z differ from generations that came before them. In general, members of Generation Z “tend to prefer an à la carte approach to education” with hands-on experiences, and they prefer customized feedback that is actionable, Dr. Dua explained.
“As a medical educator, there are different demands, and these are changing over time, so we have to figure out how we can best serve them and educate them,” she said.
This also means connecting with younger generations on social media. A research letter published in JAMA Network Open in 2021 found a minority of 650 physicians across 14 specialties had a presence on social media platforms, with 44.9% of physicians surveyed present on LinkedIn, 23.4% on Facebook, 18.6% of on Twitter, and 14.9% on ResearchGate. “There is a lot of room to grow, and this is where some of our future teaching is headed,” Dr. Dua said.
Future of rheumatology education
Does this mean rheumatologists should start dancing in TikTok videos? Maybe not, but Dr. Dua noted there are ways to bring understanding, recall, comprehension, and behavioral change through active learning, spaced learning, case-based modules, podcasts, videos, and other educational strategies.
“We need to find ways to engage our learners and connect with them and teach them,” she said.
Rheumatologists are already bringing innovation to the education space with initiatives like educational podcasts, remote learning developed during the COVID-19 pandemic, development of rheumatology Objective Structured Clinical Examinations using challenging patient scenarios, and other virtual learning opportunities. “We really have been forced to push the envelope,” Dr. Dua said.
“The future of medical education is here. It’s exciting. Embrace it,” she said.
Training nurse practitioners and physician assistants?
Commenting on the shortage of rheumatologists, Philip J. Mease, MD, clinical professor at the University of Washington and director of rheumatology research at Swedish Medical Center, both in Seattle, said one answer to the problem may be training more nurse practitioners (NPs) and physician assistants (PAs) to bridge the gap.
“Some are suggesting that part of the answer to the deficiency of rheumatologists will be having two NPs or PAs to every single rheumatologist that there is out there,” he said. “I work with three, and the issue of ... getting access to them when they are in school to demonstrate how sexy rheumatology is, is something that is deficient, way deficient.” Rheumatologists should be putting themselves out there with preceptorships and lectures to recruit more NPs and PAs to rheumatology, he explained. “That’s a 24/7 process.”
Dr. Dua, who is cochair of the E-Learning Subcommittee within the ACR Workforce Solutions Steering Committee, said the subcomittee’s focus has been connecting with primary care doctors, pediatricians, NPs, and PAs to “expand who can provide some rheumatologic care.”
Lindsay Orme, MD, a family medicine doctor from Caldwell, Idaho, shared her experience serving as faculty for a family medicine residency program, training family medicine doctors in rural areas.
“Our curriculum hasn’t had a section for what trainees are expected to learn in rheumatology. When I did the same program years ago in Idaho, it was very well defined: What I should know how to do without consulting a cardiologist, what I should know how to do without consulting an obstetrician, what I should be able to manage in terms of [chronic kidney disease] before referring to nephrology,” she explained. “No one ever taught me what I could manage in rheumatology.
“I do think we need to find some defined areas that we’re more comfortable teaching primary care doctors to manage because there is no one – there are no rheumatologists in Boise or any of the surrounding towns that accept Medicaid patients now. They are all expected to go 250 miles away,” she said.
“That’s a major, major problem,” Dr. Dua acknowledged. “Really, for me, the goal is to develop resources that you can tap into to be able to at least figure out where things stand, and at least bide time until they can get in with that rheumatologist 250 miles away and make sure that you’re getting the training, or feel comfortable with whatever it is you’re forced to manage from a rheumatologic sense.”
More engagement, more adaptation
Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said one thing he’s noticed over the years is that, as time spent in the hospital has decreased, the time residents and fellows spend with practitioners in front of patients has also decreased. “It just isn’t there, and that’s where you really learn,” he said.
“You are 100% correct the two generations are different. What I think is important in life is very different than what the fellows think is different in life at this point, and how much work I’m willing to put in or how much work they’re willing to put in, in the same way, is very different,” he explained. “What they want to spend their time on, I don’t, and vice versa. We do have to adapt, but I do think that they need more time in front of patients with very experienced physicians.”
Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said if education is to move forward, “it’s got to change dramatically.”
“The competencies aren’t always knowledge,” he said. “Knowledge has now been replaced by everything at your fingertips. I don’t need to know all the formulas and everything right now.”
Engagement should be the “main statistic that we need to be striving for,” Dr. Cush explained. “Engagement as the measure of ... education’s value, I think, is where it has to go.”
Dr. Dua reported being a consultant and serving on an advisory board for Sanofi, Novartis, AbbVie, and Chemocentryx/Amgen.
To address the growing workforce shortage in rheumatology, medical educators will have to adapt and learn how to train a new generation of rheumatologists, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.
Anisha B. Dua, MD, an associate professor of rheumatology at Northwestern University, Chicago, told attendees she is “heavily invested in the training of our future rheumatologists” and strives to help them “operate at the top of the level across the spectrum.”
“They’re carrying forward our field,” Dr. Dua said. “We need to propagate our field and we need them to go out and serve and continue to make rheumatology awesome.”
The American College of Rheumatology’s 2015 workforce study estimates that by 2030, there will be a shortage of more than 4,000 rheumatologists in the United States.
Rheumatology may have inadvertently created the problem through rheumatologists diagnosing disease earlier and prescribing better treatments, with patients subsequently living longer with disease, she noted. Compounding the problem is an increasing number of rheumatologists looking to retire over the next decade and the continued need for care in rural areas where there are few practicing rheumatologists.
Interest in rheumatology is increasing
The good news is there is increasing interest in the field. “This has really shifted, I would say, from about 10 years ago when I was looking at fellowships,” Dr. Dua said. “It’s not really an interest problem. But the issue is that the training programs and slots don’t necessarily exist to fill the gap of the people who are leaving the field.”
The key to bringing more people into rheumatology is to understand how Millennials and Generation Z differ from generations that came before them. In general, members of Generation Z “tend to prefer an à la carte approach to education” with hands-on experiences, and they prefer customized feedback that is actionable, Dr. Dua explained.
“As a medical educator, there are different demands, and these are changing over time, so we have to figure out how we can best serve them and educate them,” she said.
This also means connecting with younger generations on social media. A research letter published in JAMA Network Open in 2021 found a minority of 650 physicians across 14 specialties had a presence on social media platforms, with 44.9% of physicians surveyed present on LinkedIn, 23.4% on Facebook, 18.6% of on Twitter, and 14.9% on ResearchGate. “There is a lot of room to grow, and this is where some of our future teaching is headed,” Dr. Dua said.
Future of rheumatology education
Does this mean rheumatologists should start dancing in TikTok videos? Maybe not, but Dr. Dua noted there are ways to bring understanding, recall, comprehension, and behavioral change through active learning, spaced learning, case-based modules, podcasts, videos, and other educational strategies.
“We need to find ways to engage our learners and connect with them and teach them,” she said.
Rheumatologists are already bringing innovation to the education space with initiatives like educational podcasts, remote learning developed during the COVID-19 pandemic, development of rheumatology Objective Structured Clinical Examinations using challenging patient scenarios, and other virtual learning opportunities. “We really have been forced to push the envelope,” Dr. Dua said.
“The future of medical education is here. It’s exciting. Embrace it,” she said.
Training nurse practitioners and physician assistants?
Commenting on the shortage of rheumatologists, Philip J. Mease, MD, clinical professor at the University of Washington and director of rheumatology research at Swedish Medical Center, both in Seattle, said one answer to the problem may be training more nurse practitioners (NPs) and physician assistants (PAs) to bridge the gap.
“Some are suggesting that part of the answer to the deficiency of rheumatologists will be having two NPs or PAs to every single rheumatologist that there is out there,” he said. “I work with three, and the issue of ... getting access to them when they are in school to demonstrate how sexy rheumatology is, is something that is deficient, way deficient.” Rheumatologists should be putting themselves out there with preceptorships and lectures to recruit more NPs and PAs to rheumatology, he explained. “That’s a 24/7 process.”
Dr. Dua, who is cochair of the E-Learning Subcommittee within the ACR Workforce Solutions Steering Committee, said the subcomittee’s focus has been connecting with primary care doctors, pediatricians, NPs, and PAs to “expand who can provide some rheumatologic care.”
Lindsay Orme, MD, a family medicine doctor from Caldwell, Idaho, shared her experience serving as faculty for a family medicine residency program, training family medicine doctors in rural areas.
“Our curriculum hasn’t had a section for what trainees are expected to learn in rheumatology. When I did the same program years ago in Idaho, it was very well defined: What I should know how to do without consulting a cardiologist, what I should know how to do without consulting an obstetrician, what I should be able to manage in terms of [chronic kidney disease] before referring to nephrology,” she explained. “No one ever taught me what I could manage in rheumatology.
“I do think we need to find some defined areas that we’re more comfortable teaching primary care doctors to manage because there is no one – there are no rheumatologists in Boise or any of the surrounding towns that accept Medicaid patients now. They are all expected to go 250 miles away,” she said.
“That’s a major, major problem,” Dr. Dua acknowledged. “Really, for me, the goal is to develop resources that you can tap into to be able to at least figure out where things stand, and at least bide time until they can get in with that rheumatologist 250 miles away and make sure that you’re getting the training, or feel comfortable with whatever it is you’re forced to manage from a rheumatologic sense.”
More engagement, more adaptation
Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said one thing he’s noticed over the years is that, as time spent in the hospital has decreased, the time residents and fellows spend with practitioners in front of patients has also decreased. “It just isn’t there, and that’s where you really learn,” he said.
“You are 100% correct the two generations are different. What I think is important in life is very different than what the fellows think is different in life at this point, and how much work I’m willing to put in or how much work they’re willing to put in, in the same way, is very different,” he explained. “What they want to spend their time on, I don’t, and vice versa. We do have to adapt, but I do think that they need more time in front of patients with very experienced physicians.”
Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said if education is to move forward, “it’s got to change dramatically.”
“The competencies aren’t always knowledge,” he said. “Knowledge has now been replaced by everything at your fingertips. I don’t need to know all the formulas and everything right now.”
Engagement should be the “main statistic that we need to be striving for,” Dr. Cush explained. “Engagement as the measure of ... education’s value, I think, is where it has to go.”
Dr. Dua reported being a consultant and serving on an advisory board for Sanofi, Novartis, AbbVie, and Chemocentryx/Amgen.
To address the growing workforce shortage in rheumatology, medical educators will have to adapt and learn how to train a new generation of rheumatologists, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.
Anisha B. Dua, MD, an associate professor of rheumatology at Northwestern University, Chicago, told attendees she is “heavily invested in the training of our future rheumatologists” and strives to help them “operate at the top of the level across the spectrum.”
“They’re carrying forward our field,” Dr. Dua said. “We need to propagate our field and we need them to go out and serve and continue to make rheumatology awesome.”
The American College of Rheumatology’s 2015 workforce study estimates that by 2030, there will be a shortage of more than 4,000 rheumatologists in the United States.
Rheumatology may have inadvertently created the problem through rheumatologists diagnosing disease earlier and prescribing better treatments, with patients subsequently living longer with disease, she noted. Compounding the problem is an increasing number of rheumatologists looking to retire over the next decade and the continued need for care in rural areas where there are few practicing rheumatologists.
Interest in rheumatology is increasing
The good news is there is increasing interest in the field. “This has really shifted, I would say, from about 10 years ago when I was looking at fellowships,” Dr. Dua said. “It’s not really an interest problem. But the issue is that the training programs and slots don’t necessarily exist to fill the gap of the people who are leaving the field.”
The key to bringing more people into rheumatology is to understand how Millennials and Generation Z differ from generations that came before them. In general, members of Generation Z “tend to prefer an à la carte approach to education” with hands-on experiences, and they prefer customized feedback that is actionable, Dr. Dua explained.
“As a medical educator, there are different demands, and these are changing over time, so we have to figure out how we can best serve them and educate them,” she said.
This also means connecting with younger generations on social media. A research letter published in JAMA Network Open in 2021 found a minority of 650 physicians across 14 specialties had a presence on social media platforms, with 44.9% of physicians surveyed present on LinkedIn, 23.4% on Facebook, 18.6% of on Twitter, and 14.9% on ResearchGate. “There is a lot of room to grow, and this is where some of our future teaching is headed,” Dr. Dua said.
Future of rheumatology education
Does this mean rheumatologists should start dancing in TikTok videos? Maybe not, but Dr. Dua noted there are ways to bring understanding, recall, comprehension, and behavioral change through active learning, spaced learning, case-based modules, podcasts, videos, and other educational strategies.
“We need to find ways to engage our learners and connect with them and teach them,” she said.
Rheumatologists are already bringing innovation to the education space with initiatives like educational podcasts, remote learning developed during the COVID-19 pandemic, development of rheumatology Objective Structured Clinical Examinations using challenging patient scenarios, and other virtual learning opportunities. “We really have been forced to push the envelope,” Dr. Dua said.
“The future of medical education is here. It’s exciting. Embrace it,” she said.
Training nurse practitioners and physician assistants?
Commenting on the shortage of rheumatologists, Philip J. Mease, MD, clinical professor at the University of Washington and director of rheumatology research at Swedish Medical Center, both in Seattle, said one answer to the problem may be training more nurse practitioners (NPs) and physician assistants (PAs) to bridge the gap.
“Some are suggesting that part of the answer to the deficiency of rheumatologists will be having two NPs or PAs to every single rheumatologist that there is out there,” he said. “I work with three, and the issue of ... getting access to them when they are in school to demonstrate how sexy rheumatology is, is something that is deficient, way deficient.” Rheumatologists should be putting themselves out there with preceptorships and lectures to recruit more NPs and PAs to rheumatology, he explained. “That’s a 24/7 process.”
Dr. Dua, who is cochair of the E-Learning Subcommittee within the ACR Workforce Solutions Steering Committee, said the subcomittee’s focus has been connecting with primary care doctors, pediatricians, NPs, and PAs to “expand who can provide some rheumatologic care.”
Lindsay Orme, MD, a family medicine doctor from Caldwell, Idaho, shared her experience serving as faculty for a family medicine residency program, training family medicine doctors in rural areas.
“Our curriculum hasn’t had a section for what trainees are expected to learn in rheumatology. When I did the same program years ago in Idaho, it was very well defined: What I should know how to do without consulting a cardiologist, what I should know how to do without consulting an obstetrician, what I should be able to manage in terms of [chronic kidney disease] before referring to nephrology,” she explained. “No one ever taught me what I could manage in rheumatology.
“I do think we need to find some defined areas that we’re more comfortable teaching primary care doctors to manage because there is no one – there are no rheumatologists in Boise or any of the surrounding towns that accept Medicaid patients now. They are all expected to go 250 miles away,” she said.
“That’s a major, major problem,” Dr. Dua acknowledged. “Really, for me, the goal is to develop resources that you can tap into to be able to at least figure out where things stand, and at least bide time until they can get in with that rheumatologist 250 miles away and make sure that you’re getting the training, or feel comfortable with whatever it is you’re forced to manage from a rheumatologic sense.”
More engagement, more adaptation
Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said one thing he’s noticed over the years is that, as time spent in the hospital has decreased, the time residents and fellows spend with practitioners in front of patients has also decreased. “It just isn’t there, and that’s where you really learn,” he said.
“You are 100% correct the two generations are different. What I think is important in life is very different than what the fellows think is different in life at this point, and how much work I’m willing to put in or how much work they’re willing to put in, in the same way, is very different,” he explained. “What they want to spend their time on, I don’t, and vice versa. We do have to adapt, but I do think that they need more time in front of patients with very experienced physicians.”
Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said if education is to move forward, “it’s got to change dramatically.”
“The competencies aren’t always knowledge,” he said. “Knowledge has now been replaced by everything at your fingertips. I don’t need to know all the formulas and everything right now.”
Engagement should be the “main statistic that we need to be striving for,” Dr. Cush explained. “Engagement as the measure of ... education’s value, I think, is where it has to go.”
Dr. Dua reported being a consultant and serving on an advisory board for Sanofi, Novartis, AbbVie, and Chemocentryx/Amgen.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>162291</fileName> <TBEID>0C0487FC.SIG</TBEID> <TBUniqueIdentifier>MD_0C0487FC</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname>RWCS 23 Dua rheum edu</storyname> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20230223T090452</QCDate> <firstPublished>20230223T092923</firstPublished> <LastPublished>20230223T092923</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20230223T092923</CMSDate> <articleSource>FROM RWCS 2023</articleSource> <facebookInfo/> <meetingNumber>4660-23</meetingNumber> <byline>Jeff Craven</byline> <bylineText>JEFF CRAVEN</bylineText> <bylineFull>JEFF CRAVEN</bylineFull> <bylineTitleText>MDedge News</bylineTitleText> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>To address the growing workforce shortage in rheumatology, medical educators will have to adapt and learn how to train a new generation of rheumatologists, acco</metaDescription> <articlePDF/> <teaserImage>257311</teaserImage> <teaser>Training the next generation of rheumatologists will involve giving and listening to more feedback as well as using new tools to boost engagement, retention, and behavioral changes. </teaser> <title>Adaptations to education, training vital to alleviating rheumatologist shortage</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>rn</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">26</term> </publications> <sections> <term canonical="true">53</term> <term>39313</term> </sections> <topics> <term canonical="true">38029</term> </topics> <links> <link> <itemClass qcode="ninat:picture"/> <altRep contenttype="image/jpeg">images/2400d6ad.jpg</altRep> <description role="drol:caption">Dr. Anisha Dua</description> <description role="drol:credit">M. Alexander Otto</description> </link> </links> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Adaptations to education, training vital to alleviating rheumatologist shortage</title> <deck/> </itemMeta> <itemContent> <p>To address the growing workforce shortage in rheumatology, medical educators will have to adapt and learn how to train a new generation of rheumatologists, according to a speaker at the 2023 Rheumatology Winter Clinical Symposium.</p> <p>Anisha B. Dua, MD, an associate professor of rheumatology at Northwestern University, Chicago, told attendees she is “heavily invested in the training of our future rheumatologists” and strives to help them “operate at the top of the level across the spectrum.”<br/><br/>[[{"fid":"257311","view_mode":"medstat_image_flush_right","fields":{"format":"medstat_image_flush_right","field_file_image_alt_text[und][0][value]":"Dr. Anisha Dua, associate professor of rheumatology at Northwestern University, Chicago","field_file_image_credit[und][0][value]":"M. Alexander Otto","field_file_image_caption[und][0][value]":"Dr. Anisha Dua"},"type":"media","attributes":{"class":"media-element file-medstat_image_flush_right"}}]]“They’re carrying forward our field,” Dr. Dua said. “We need to propagate our field and we need them to go out and serve and continue to make rheumatology awesome.”<br/><br/>The <span class="Hyperlink"><a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.23518">American College of Rheumatology’s 2015 workforce study</a></span> estimates that by 2030, there will be a shortage of more than 4,000 rheumatologists in the United States. <br/><br/>Rheumatology may have inadvertently created the problem through rheumatologists diagnosing disease earlier and prescribing better treatments, with patients subsequently living longer with disease, she noted. Compounding the problem is an increasing number of rheumatologists looking to retire over the next decade and the continued need for care in rural areas where there are few practicing rheumatologists. <br/><br/></p> <h2>Interest in rheumatology is increasing</h2> <p>The good news is there is increasing interest in the field. “This has really shifted, I would say, from about 10 years ago when I was looking at fellowships,” Dr. Dua said. “It’s not really an interest problem. But the issue is that the training programs and slots don’t necessarily exist to fill the gap of the people who are leaving the field.”</p> <p>The key to bringing more people into rheumatology is to understand how Millennials and Generation Z differ from generations that came before them. In general, members of Generation Z “tend to prefer an à la carte approach to education” with hands-on experiences, and they prefer customized feedback that is actionable, Dr. Dua explained. <br/><br/>“As a medical educator, there are different demands, and these are changing over time, so we have to figure out how we can best serve them and educate them,” she said.<br/><br/>This also means connecting with younger generations on social media. A <span class="Hyperlink"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782171">research letter</a></span> published in JAMA Network Open in 2021 found a minority of 650 physicians across 14 specialties had a presence on social media platforms, with 44.9% of physicians surveyed present on LinkedIn, 23.4% on Facebook, 18.6% of on Twitter, and 14.9% on ResearchGate. “There is a lot of room to grow, and this is where some of our future teaching is headed,” Dr. Dua said.<br/><br/></p> <h2>Future of rheumatology education</h2> <p>Does this mean rheumatologists should start dancing in TikTok videos? Maybe not, but Dr. Dua noted there are ways to bring understanding, recall, comprehension, and behavioral change through active learning, spaced learning, case-based modules, podcasts, videos, and other educational strategies.<br/><br/>“We need to find ways to engage our learners and connect with them and teach them,” she said.<br/><br/>Rheumatologists are already bringing innovation to the education space with initiatives like educational podcasts, remote learning developed during the COVID-19 pandemic, development of rheumatology Objective Structured Clinical Examinations using challenging patient scenarios, and other virtual learning opportunities. “We really have been forced to push the envelope,” Dr. Dua said.<br/><br/>“The future of medical education is here. It’s exciting. Embrace it,” she said.<br/><br/></p> <h2>Training nurse practitioners and physician assistants?</h2> <p>Commenting on the shortage of rheumatologists, Philip J. Mease, MD, clinical professor at the University of Washington and director of rheumatology research at Swedish Medical Center, both in Seattle, said one answer to the problem may be training more nurse practitioners (NPs) and physician assistants (PAs) to bridge the gap.</p> <p>“Some are suggesting that part of the answer to the deficiency of rheumatologists will be having two NPs or PAs to every single rheumatologist that there is out there,” he said. “I work with three, and the issue of ... getting access to them when they are in school to demonstrate how sexy rheumatology is, is something that is deficient, way deficient.” Rheumatologists should be putting themselves out there with preceptorships and lectures to recruit more NPs and PAs to rheumatology, he explained. “That’s a 24/7 process.”<br/><br/>Dr. Dua, who is cochair of the E-Learning Subcommittee within the ACR Workforce Solutions Steering Committee, said the subcomittee’s focus has been connecting with primary care doctors, pediatricians, NPs, and PAs to “expand who can provide some rheumatologic care.”<br/><br/><span class="Hyperlink"><a href="https://westvalleymedctr.com/physicians/profile/Dr-Lindsay-K-Orme-MD">Lindsay Orme, MD</a></span>, a family medicine doctor from Caldwell, Idaho, shared her experience serving as faculty for a family medicine residency program, training family medicine doctors in rural areas. <br/><br/>“Our curriculum hasn’t had a section for what trainees are expected to learn in rheumatology. When I did the same program years ago in Idaho, it was very well defined: What I should know how to do without consulting a cardiologist, what I should know how to do without consulting an obstetrician, what I should be able to manage in terms of [chronic kidney disease] before referring to nephrology,” she explained. “No one ever taught me what I could manage in rheumatology.<br/><br/>“I do think we need to find some defined areas that we’re more comfortable teaching primary care doctors to manage because there is no one – there are no rheumatologists in Boise or any of the surrounding towns that accept Medicaid patients now. They are all expected to go 250 miles away,” she said.<br/><br/>“That’s a major, major problem,” Dr. Dua acknowledged. “Really, for me, the goal is to develop resources that you can tap into to be able to at least figure out where things stand, and at least bide time until they can get in with that rheumatologist 250 miles away and make sure that you’re getting the training, or feel comfortable with whatever it is you’re forced to manage from a rheumatologic sense.”<br/><br/></p> <h2>More engagement, more adaptation</h2> <p>Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said one thing he’s noticed over the years is that, as time spent in the hospital has decreased, the time residents and fellows spend with practitioners in front of patients has also decreased. “It just isn’t there, and that’s where you really learn,” he said.</p> <p>“You are 100% correct the two generations are different. What I think is important in life is very different than what the fellows think is different in life at this point, and how much work I’m willing to put in or how much work they’re willing to put in, in the same way, is very different,” he explained. “What they want to spend their time on, I don’t, and vice versa. We do have to adapt, but I do think that they need more time in front of patients with very experienced physicians.”<br/><br/>Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said if education is to move forward, “it’s got to change dramatically.” <br/><br/>“The competencies aren’t always knowledge,” he said. “Knowledge has now been replaced by everything at your fingertips. I don’t need to know all the formulas and everything right now.”<br/><br/>Engagement should be the “main statistic that we need to be striving for,” Dr. Cush explained. “Engagement as the measure of ... education’s value, I think, is where it has to go.”<br/><br/>Dr. Dua reported being a consultant and serving on an advisory board for Sanofi, Novartis, AbbVie, and Chemocentryx/Amgen.</p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>
FROM RWCS 2023
Telemedicine usage still high among rheumatologists as interest wanes in other specialties
There was an explosion in the use of telemedicine during the COVID-19 pandemic, but usage has stabilized and varies between specialties. However, telemedicine use is still somewhat high among rheumatologists, according to speakers at the 2023 Rheumatology Winter Clinical Symposium.
Speaking in general about the future of rheumatology, Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said it is up to rheumatologists to adapt to the changing winds in the specialty.
“The future is going to happen no matter what, so the question is, are you going to go along with it? Are you going to be a part of it? Are you going to be resistant to it?” Dr. Cush asked attendees. “Your recent experience with COVID would tell you maybe what your path is going to be if you’re dying to get back to the way it once was.”
Rheumatologists can expect changes in where they work, how they’re paid, increases in their workload, and new innovations in connecting with patients, he said.
“You’re going to be integrating a new style of medicine, you’re going to be digitally connected,” he explained. “All these networks are going to be working together to make you supposedly better at what you do, or maybe they’re working together to make you obsolete – and I think you better start protecting your space.”
One major area of change, telemedicine, already occurred as a result of the COVID-19 pandemic and will “begin to dominate” over the next decade, Dr. Cush said. An analysis conducted by consulting firm McKinsey & Company found telehealth usage increased 78-fold between February and April 2020 before leveling off at a 38-fold higher rate, compared with prepandemic levels. In the same analysis, rheumatology ranked third in terms of telehealth usage claims behind psychiatry and substance use disorder treatment, Dr. Cush observed, as other specialties have “fallen off quite a bit.”
“The common denominators are chronic care, cognitive care, nonprocedural care, pattern recognition, and monitoring, and this is what you do,” he said. “This is why, in many ways, for you to abandon telemedicine I think is a gigantic mistake.”
Changes to telemedicine
The most immediate change to telemedicine will come when the Biden administration officially ends the COVID-19 public health emergency in May 2023, and temporary telehealth services will be extended for approximately 5 months after the end of the public health emergency. Legislation passed by Congress will ensure some of the flexibilities in telemedicine will be extended until the end of December 2024.
Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said he sees telemedicine as persisting even after the official COVID-19 public health emergency ends. “There’s a lot of push from the American Medical Association, from the American College of Physicians. You’re going to see people – this will not go away because [there’s] also going to be that demand.”
Despite decreased usage since April 2020, telehealth was estimated to be a $60 billion industry in 2022 and will likely increase over the next decade, Dr. Cush noted. “I question [the decline] because I think it still is a major part of your [future in] 2033.”
The number of physicians who have at least three licenses to practice in other U.S. states increased from 50,454 in 2010 to 72,752 in 2020, and that trend will continue, Dr. Wells explained. It is now becoming easier for physicians to become licensed in other states with companies like CompHealth that offer services to simplify obtaining medical licenses with states that participate in the Interstate Medical Licensure Compact.
“It’s a telemedicine easy pass,” Dr. Cush said.
Concerns in telemedicine
Commenting on the presentation, Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at the Hospital for Special Surgery (HSS), both in New York, pointed out that because telemedicine is governed by U.S. states, rather than the federal government, a physician needs to be licensed in the state where the patient is located. While many states relaxed their restrictions during COVID-19, as states began tightening their restrictions later, “many physicians didn’t want to have three licenses,” he said.
“There’s an expense in getting three licenses. There’s an expense in obtaining it and maintaining it, and the reimbursement for the telemedicine visit did not reach that expectation,” Dr. Gibofsky explained. With the exception of the orthopedic surgeons at HSS who practice in New York and a satellite office in Florida, none of the surgeons at his center have obtained more than one license to practice telemedicine in other states.
“Our volume of telemedicine at HSS has remained about the same at 30%, but fewer physicians are doing it because they don’t want to maintain multiple licensures,” he said. “So don’t overlook the role of legal concerns in terms of who’s going to be allowed to do what where. Your talk was great in terms of an exuberance of what’s going to be available, but it’s not going to relieve the physician from the burden of being responsible for their use.”
Eric Ruderman, MD, professor of rheumatology at Northwestern University, Chicago, asked the presenters about the balance between seeing patients for virtual and in-person visits. “The question is what’s the sweet spot? Are there people you’re willing to see virtually forever?” he asked, noting that he has patients scheduling telemedicine visits that he hasn’t seen since before the COVID-19 pandemic.
[embed:render:related:node:237288]
“That’s not going to work for me. At some point, you have to lay hands on people,” he said.
Dr. Wells said his current practice is 40% virtual, and his staff converts potential no-shows into a telemedicine consultation over the phone. “My no-show rate has gone down to zero. Somebody’s scheduled for a visit, they don’t show up, my [medical assistants] get them on the phone, they put them on hold, tee up the refills. I turn them into a telephone call,” he said. “We don’t accept the no-show at all because we can do a telephone [consultation].”
In Dr. Cush’s practice, he alternates telemedicine visits with in-person visits. “If you come back for two videos in a row, you’re catching hell from me for that,” he said. Responding to how Dr. Wells incorporates telemedicine into his practice, Dr. Cush said many rheumatologists “don’t have the setups to support the care, and that’s why it’s hard to do and that’s why we’re not as great as we could be.”
“This is the way we were trained. We’re used to seeing these patients in the clinic that often. Not every single patient needs to be seen that frequently if they’re stable and doing fine,” Dr. Wells countered.
Dr. Cush and Dr. Wells reported having financial relationships with numerous pharmaceutical companies.
There was an explosion in the use of telemedicine during the COVID-19 pandemic, but usage has stabilized and varies between specialties. However, telemedicine use is still somewhat high among rheumatologists, according to speakers at the 2023 Rheumatology Winter Clinical Symposium.
Speaking in general about the future of rheumatology, Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said it is up to rheumatologists to adapt to the changing winds in the specialty.
“The future is going to happen no matter what, so the question is, are you going to go along with it? Are you going to be a part of it? Are you going to be resistant to it?” Dr. Cush asked attendees. “Your recent experience with COVID would tell you maybe what your path is going to be if you’re dying to get back to the way it once was.”
Rheumatologists can expect changes in where they work, how they’re paid, increases in their workload, and new innovations in connecting with patients, he said.
“You’re going to be integrating a new style of medicine, you’re going to be digitally connected,” he explained. “All these networks are going to be working together to make you supposedly better at what you do, or maybe they’re working together to make you obsolete – and I think you better start protecting your space.”
One major area of change, telemedicine, already occurred as a result of the COVID-19 pandemic and will “begin to dominate” over the next decade, Dr. Cush said. An analysis conducted by consulting firm McKinsey & Company found telehealth usage increased 78-fold between February and April 2020 before leveling off at a 38-fold higher rate, compared with prepandemic levels. In the same analysis, rheumatology ranked third in terms of telehealth usage claims behind psychiatry and substance use disorder treatment, Dr. Cush observed, as other specialties have “fallen off quite a bit.”
“The common denominators are chronic care, cognitive care, nonprocedural care, pattern recognition, and monitoring, and this is what you do,” he said. “This is why, in many ways, for you to abandon telemedicine I think is a gigantic mistake.”
Changes to telemedicine
The most immediate change to telemedicine will come when the Biden administration officially ends the COVID-19 public health emergency in May 2023, and temporary telehealth services will be extended for approximately 5 months after the end of the public health emergency. Legislation passed by Congress will ensure some of the flexibilities in telemedicine will be extended until the end of December 2024.
Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said he sees telemedicine as persisting even after the official COVID-19 public health emergency ends. “There’s a lot of push from the American Medical Association, from the American College of Physicians. You’re going to see people – this will not go away because [there’s] also going to be that demand.”
Despite decreased usage since April 2020, telehealth was estimated to be a $60 billion industry in 2022 and will likely increase over the next decade, Dr. Cush noted. “I question [the decline] because I think it still is a major part of your [future in] 2033.”
The number of physicians who have at least three licenses to practice in other U.S. states increased from 50,454 in 2010 to 72,752 in 2020, and that trend will continue, Dr. Wells explained. It is now becoming easier for physicians to become licensed in other states with companies like CompHealth that offer services to simplify obtaining medical licenses with states that participate in the Interstate Medical Licensure Compact.
“It’s a telemedicine easy pass,” Dr. Cush said.
Concerns in telemedicine
Commenting on the presentation, Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at the Hospital for Special Surgery (HSS), both in New York, pointed out that because telemedicine is governed by U.S. states, rather than the federal government, a physician needs to be licensed in the state where the patient is located. While many states relaxed their restrictions during COVID-19, as states began tightening their restrictions later, “many physicians didn’t want to have three licenses,” he said.
“There’s an expense in getting three licenses. There’s an expense in obtaining it and maintaining it, and the reimbursement for the telemedicine visit did not reach that expectation,” Dr. Gibofsky explained. With the exception of the orthopedic surgeons at HSS who practice in New York and a satellite office in Florida, none of the surgeons at his center have obtained more than one license to practice telemedicine in other states.
“Our volume of telemedicine at HSS has remained about the same at 30%, but fewer physicians are doing it because they don’t want to maintain multiple licensures,” he said. “So don’t overlook the role of legal concerns in terms of who’s going to be allowed to do what where. Your talk was great in terms of an exuberance of what’s going to be available, but it’s not going to relieve the physician from the burden of being responsible for their use.”
Eric Ruderman, MD, professor of rheumatology at Northwestern University, Chicago, asked the presenters about the balance between seeing patients for virtual and in-person visits. “The question is what’s the sweet spot? Are there people you’re willing to see virtually forever?” he asked, noting that he has patients scheduling telemedicine visits that he hasn’t seen since before the COVID-19 pandemic.
[embed:render:related:node:237288]
“That’s not going to work for me. At some point, you have to lay hands on people,” he said.
Dr. Wells said his current practice is 40% virtual, and his staff converts potential no-shows into a telemedicine consultation over the phone. “My no-show rate has gone down to zero. Somebody’s scheduled for a visit, they don’t show up, my [medical assistants] get them on the phone, they put them on hold, tee up the refills. I turn them into a telephone call,” he said. “We don’t accept the no-show at all because we can do a telephone [consultation].”
In Dr. Cush’s practice, he alternates telemedicine visits with in-person visits. “If you come back for two videos in a row, you’re catching hell from me for that,” he said. Responding to how Dr. Wells incorporates telemedicine into his practice, Dr. Cush said many rheumatologists “don’t have the setups to support the care, and that’s why it’s hard to do and that’s why we’re not as great as we could be.”
“This is the way we were trained. We’re used to seeing these patients in the clinic that often. Not every single patient needs to be seen that frequently if they’re stable and doing fine,” Dr. Wells countered.
Dr. Cush and Dr. Wells reported having financial relationships with numerous pharmaceutical companies.
There was an explosion in the use of telemedicine during the COVID-19 pandemic, but usage has stabilized and varies between specialties. However, telemedicine use is still somewhat high among rheumatologists, according to speakers at the 2023 Rheumatology Winter Clinical Symposium.
Speaking in general about the future of rheumatology, Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said it is up to rheumatologists to adapt to the changing winds in the specialty.
“The future is going to happen no matter what, so the question is, are you going to go along with it? Are you going to be a part of it? Are you going to be resistant to it?” Dr. Cush asked attendees. “Your recent experience with COVID would tell you maybe what your path is going to be if you’re dying to get back to the way it once was.”
Rheumatologists can expect changes in where they work, how they’re paid, increases in their workload, and new innovations in connecting with patients, he said.
“You’re going to be integrating a new style of medicine, you’re going to be digitally connected,” he explained. “All these networks are going to be working together to make you supposedly better at what you do, or maybe they’re working together to make you obsolete – and I think you better start protecting your space.”
One major area of change, telemedicine, already occurred as a result of the COVID-19 pandemic and will “begin to dominate” over the next decade, Dr. Cush said. An analysis conducted by consulting firm McKinsey & Company found telehealth usage increased 78-fold between February and April 2020 before leveling off at a 38-fold higher rate, compared with prepandemic levels. In the same analysis, rheumatology ranked third in terms of telehealth usage claims behind psychiatry and substance use disorder treatment, Dr. Cush observed, as other specialties have “fallen off quite a bit.”
“The common denominators are chronic care, cognitive care, nonprocedural care, pattern recognition, and monitoring, and this is what you do,” he said. “This is why, in many ways, for you to abandon telemedicine I think is a gigantic mistake.”
Changes to telemedicine
The most immediate change to telemedicine will come when the Biden administration officially ends the COVID-19 public health emergency in May 2023, and temporary telehealth services will be extended for approximately 5 months after the end of the public health emergency. Legislation passed by Congress will ensure some of the flexibilities in telemedicine will be extended until the end of December 2024.
Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said he sees telemedicine as persisting even after the official COVID-19 public health emergency ends. “There’s a lot of push from the American Medical Association, from the American College of Physicians. You’re going to see people – this will not go away because [there’s] also going to be that demand.”
Despite decreased usage since April 2020, telehealth was estimated to be a $60 billion industry in 2022 and will likely increase over the next decade, Dr. Cush noted. “I question [the decline] because I think it still is a major part of your [future in] 2033.”
The number of physicians who have at least three licenses to practice in other U.S. states increased from 50,454 in 2010 to 72,752 in 2020, and that trend will continue, Dr. Wells explained. It is now becoming easier for physicians to become licensed in other states with companies like CompHealth that offer services to simplify obtaining medical licenses with states that participate in the Interstate Medical Licensure Compact.
“It’s a telemedicine easy pass,” Dr. Cush said.
Concerns in telemedicine
Commenting on the presentation, Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at the Hospital for Special Surgery (HSS), both in New York, pointed out that because telemedicine is governed by U.S. states, rather than the federal government, a physician needs to be licensed in the state where the patient is located. While many states relaxed their restrictions during COVID-19, as states began tightening their restrictions later, “many physicians didn’t want to have three licenses,” he said.
“There’s an expense in getting three licenses. There’s an expense in obtaining it and maintaining it, and the reimbursement for the telemedicine visit did not reach that expectation,” Dr. Gibofsky explained. With the exception of the orthopedic surgeons at HSS who practice in New York and a satellite office in Florida, none of the surgeons at his center have obtained more than one license to practice telemedicine in other states.
“Our volume of telemedicine at HSS has remained about the same at 30%, but fewer physicians are doing it because they don’t want to maintain multiple licensures,” he said. “So don’t overlook the role of legal concerns in terms of who’s going to be allowed to do what where. Your talk was great in terms of an exuberance of what’s going to be available, but it’s not going to relieve the physician from the burden of being responsible for their use.”
Eric Ruderman, MD, professor of rheumatology at Northwestern University, Chicago, asked the presenters about the balance between seeing patients for virtual and in-person visits. “The question is what’s the sweet spot? Are there people you’re willing to see virtually forever?” he asked, noting that he has patients scheduling telemedicine visits that he hasn’t seen since before the COVID-19 pandemic.
[embed:render:related:node:237288]
“That’s not going to work for me. At some point, you have to lay hands on people,” he said.
Dr. Wells said his current practice is 40% virtual, and his staff converts potential no-shows into a telemedicine consultation over the phone. “My no-show rate has gone down to zero. Somebody’s scheduled for a visit, they don’t show up, my [medical assistants] get them on the phone, they put them on hold, tee up the refills. I turn them into a telephone call,” he said. “We don’t accept the no-show at all because we can do a telephone [consultation].”
In Dr. Cush’s practice, he alternates telemedicine visits with in-person visits. “If you come back for two videos in a row, you’re catching hell from me for that,” he said. Responding to how Dr. Wells incorporates telemedicine into his practice, Dr. Cush said many rheumatologists “don’t have the setups to support the care, and that’s why it’s hard to do and that’s why we’re not as great as we could be.”
“This is the way we were trained. We’re used to seeing these patients in the clinic that often. Not every single patient needs to be seen that frequently if they’re stable and doing fine,” Dr. Wells countered.
Dr. Cush and Dr. Wells reported having financial relationships with numerous pharmaceutical companies.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>162273</fileName> <TBEID>0C048773.SIG</TBEID> <TBUniqueIdentifier>MD_0C048773</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20230221T091636</QCDate> <firstPublished>20230221T091352</firstPublished> <LastPublished>20230221T091352</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20230221T091352</CMSDate> <articleSource>FROM RWCS 2023</articleSource> <facebookInfo/> <meetingNumber>4660-23</meetingNumber> <byline>Jeff Craven</byline> <bylineText>JEFF CRAVEN</bylineText> <bylineFull>JEFF CRAVEN</bylineFull> <bylineTitleText>MDedge News</bylineTitleText> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>There was an explosion in the use of telemedicine during the COVID-19 pandemic, but usage has stabilized and varies between specialties. However, telemedicine u</metaDescription> <articlePDF/> <teaserImage>278887</teaserImage> <teaser>“For you to abandon telemedicine I think is a gigantic mistake,” Dr. Jack Cush said.</teaser> <title>Telemedicine usage still high among rheumatologists as interest wanes in other specialties</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>rn</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">26</term> </publications> <sections> <term canonical="true">53</term> <term>39313</term> </sections> <topics> <term canonical="true">38029</term> </topics> <links> <link> <itemClass qcode="ninat:picture"/> <altRep contenttype="image/jpeg">images/2400ff6e.jpg</altRep> <description role="drol:caption"/> <description role="drol:credit">FatCamera/Getty Images</description> </link> </links> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Telemedicine usage still high among rheumatologists as interest wanes in other specialties</title> <deck/> </itemMeta> <itemContent> <p>There was an explosion in the use of telemedicine during the COVID-19 pandemic, but usage has stabilized and varies between specialties. However, telemedicine use is still somewhat high among rheumatologists, according to speakers at the 2023 Rheumatology Winter Clinical Symposium.</p> <p>Speaking in general about the future of rheumatology, Jack Cush, MD, a rheumatologist based in Dallas and executive editor of RheumNow.com, said it is up to rheumatologists to adapt to the changing winds in the specialty.<br/><br/>[[{"fid":"278887","view_mode":"medstat_image_flush_left","fields":{"format":"medstat_image_flush_left","field_file_image_alt_text[und][0][value]":"African American woman has medical consultation appointment video call with her doctor.","field_file_image_credit[und][0][value]":"FatCamera/Getty Images","field_file_image_caption[und][0][value]":""},"type":"media","attributes":{"class":"media-element file-medstat_image_flush_left"}}]]“The future is going to happen no matter what, so the question is, are you going to go along with it? Are you going to be a part of it? Are you going to be resistant to it?” Dr. Cush asked attendees. “Your recent experience with COVID would tell you maybe what your path is going to be if you’re dying to get back to the way it once was.”<br/><br/>Rheumatologists can expect changes in where they work, how they’re paid, increases in their workload, and new innovations in connecting with patients, he said. <br/><br/>“You’re going to be integrating a new style of medicine, you’re going to be digitally connected,” he explained. “All these networks are going to be working together to make you supposedly better at what you do, or maybe they’re working together to make you obsolete – and I think you better start protecting your space.”<br/><br/>One major area of change, telemedicine, already occurred as a result of the COVID-19 pandemic and will “begin to dominate” over the next decade, Dr. Cush said. An <span class="Hyperlink"><a href="https://www.mckinsey.com/industries/healthcare/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality">analysis conducted by consulting firm McKinsey & Company</a></span> found telehealth usage increased 78-fold between February and April 2020 before leveling off at a 38-fold higher rate, compared with prepandemic levels. In the same analysis, rheumatology ranked third in terms of telehealth usage claims behind psychiatry and substance use disorder treatment, Dr. Cush observed, as other specialties have “fallen off quite a bit.” <br/><br/>“The common denominators are chronic care, cognitive care, nonprocedural care, pattern recognition, and monitoring, and this is what you do,” he said. “This is why, in many ways, for you to abandon telemedicine I think is a gigantic mistake.”<br/><br/></p> <h2>Changes to telemedicine</h2> <p>The most immediate change to telemedicine will come when the Biden administration officially ends the COVID-19 public health emergency in May 2023, and temporary telehealth services <a href="https://telehealth.hhs.gov/providers/policy-changes-during-the-covid-19-public-health-emergency/">will be extended</a> for approximately 5 months after the end of the public health emergency. Legislation passed by Congress will ensure some of the flexibilities in telemedicine will be extended <span class="Hyperlink"><a href="https://telehealth.hhs.gov/providers/policy-changes-during-the-covid-19-public-health-emergency/policy-changes-after-the-covid-19-public-health-emergency/">until the end of December 2024</a></span>.</p> <p>Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said he sees telemedicine as persisting even after the official COVID-19 public health emergency ends. “There’s a lot of push from the American Medical Association, from the American College of Physicians. You’re going to see people – this will not go away because [there’s] also going to be that demand.” <br/><br/>Despite decreased usage since April 2020, telehealth was estimated to be a <a href="https://www.globenewswire.com/en/news-release/2022/10/20/2537996/0/en/Global-Telehealth-Market-to-Grow-at-a-CAGR-of-35-during-2023-2033-Market-to-Expand-on-the-Back-of-the-Rising-Chronic-Disorders-and-Increasing-Geriatric-Population-across-the-Globe-.html">$60 billion industry</a> in 2022 and will likely increase over the next decade, Dr. Cush noted. “I question [the decline] because I think it still is a major part of your [future in] 2033.” <br/><br/>The <span class="Hyperlink"><a href="https://meridian.allenpress.com/jmr/article/107/2/57/469727/FSMB-Census-of-Licensed-Physicians-in-the-United">number of physicians who have at least three licenses</a></span> to practice in other U.S. states increased from 50,454 in 2010 to 72,752 in 2020, and that trend will continue, Dr. Wells explained. It is now becoming easier for physicians to become licensed in other states with <span class="Hyperlink"><a href="https://comphealth.com/resources/interstate-medical-licensure-compact">companies like CompHealth</a></span> that offer services to simplify obtaining medical licenses with states that participate in the Interstate Medical Licensure Compact.<br/><br/>“It’s a telemedicine easy pass,” Dr. Cush said.<br/><br/></p> <h2>Concerns in telemedicine</h2> <p>Commenting on the presentation, Allan Gibofsky, MD, JD, professor of medicine at Weill Cornell Medicine and codirector of the Clinic for Inflammatory Arthritis and Biologic Therapy at the Hospital for Special Surgery (HSS), both in New York, pointed out that because telemedicine is governed by U.S. states, rather than the federal government, a physician needs to be licensed in the state where the patient is located. While many states relaxed their restrictions during COVID-19, as states began tightening their restrictions later, “many physicians didn’t want to have three licenses,” he said. </p> <p>“There’s an expense in getting three licenses. There’s an expense in obtaining it and maintaining it, and the reimbursement for the telemedicine visit did not reach that expectation,” Dr. Gibofsky explained. With the exception of the orthopedic surgeons at HSS who practice in New York and a satellite office in Florida, none of the surgeons at his center have obtained more than one license to practice telemedicine in other states.<br/><br/>“Our volume of telemedicine at HSS has remained about the same at 30%, but fewer physicians are doing it because they don’t want to maintain multiple licensures,” he said. “So don’t overlook the role of legal concerns in terms of who’s going to be allowed to do what where. Your talk was great in terms of an exuberance of what’s going to be available, but it’s not going to relieve the physician from the burden of being responsible for their use.”<br/><br/>Eric Ruderman, MD, professor of rheumatology at Northwestern University, Chicago, asked the presenters about the balance between seeing patients for virtual and in-person visits. “The question is what’s the sweet spot? Are there people you’re willing to see virtually forever?” he asked, noting that he has patients scheduling telemedicine visits that he hasn’t seen since before the COVID-19 pandemic.<br/><br/>“That’s not going to work for me. At some point, you have to lay hands on people,” he said.<br/><br/>Dr. Wells said his current practice is 40% virtual, and his staff converts potential no-shows into a telemedicine consultation over the phone. “My no-show rate has gone down to zero. Somebody’s scheduled for a visit, they don’t show up, my [medical assistants] get them on the phone, they put them on hold, tee up the refills. I turn them into a telephone call,” he said. “We don’t accept the no-show at all because we can do a telephone [consultation].” <br/><br/>In Dr. Cush’s practice, he alternates telemedicine visits with in-person visits. “If you come back for two videos in a row, you’re catching hell from me for that,” he said. Responding to how Dr. Wells incorporates telemedicine into his practice, Dr. Cush said many rheumatologists “don’t have the setups to support the care, and that’s why it’s hard to do and that’s why we’re not as great as we could be.”<br/><br/>“This is the way we were trained. We’re used to seeing these patients in the clinic that often. Not every single patient needs to be seen that frequently if they’re stable and doing fine,” Dr. Wells countered.<br/><br/>Dr. Cush and Dr. Wells reported having financial relationships with numerous pharmaceutical companies.</p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>
FROM RWCS 2023
Are repeat radiographs necessary in rheumatoid and psoriatic arthritis?
Follow-up radiographs after an initial baseline reading in patients with rheumatoid arthritis or psoriatic arthritis may still show radiographic progression despite treatment with current therapies, but it’s unclear if they will affect treatment decisions between patients and doctors that may take place regardless of the radiographic information, according to arguments made for and against their usefulness in a point-counterpoint session at the 2023 Rheumatology Winter Clinical Symposium.
Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said that x-rays “reflect the history of joint pathology” and can get worse over time, correlating with disease activity and severity.
While RA does not yet have the “holy grail” of complete or true remission, Dr. Wells argued, the combination of clinical remission, laboratory remission, and imaging remission gets patients with RA close to the ideal when measured over time. “You need to continue to monitor these patients as you follow them along,” he said.
The BARFOT study, which evaluated 1,938 patients with early RA in two cohorts during 1992-1999 and again between 2000 and 2006, showed that more active treatments in the 2000s did not result in improvements in Health Assessment Questionnaire (HAQ) and pain scores, compared with patients treated in the 1990s. “You can see in some of those patients those scores do increase, and that even despite aggressive therapies that we had in 2006, you can still see some of those patients still have progression of the disease,” Dr. Wells explained. “How did they know? Because they looked.”
He also cited a study from researchers at the Mayo Clinic who examined 586 patients with RA that showed a higher prevalence of functional disability in patients with RA who also had radiographic changes, compared with patients without RA. “Radiographic changes correlate with disease severity and functional disability as well,” Dr. Wells said.
Just as prostate-specific antigen levels are used in prostate cancer screening and hemoglobin A1c is measured in diabetes management, radiographs should be used to track progression of disease in RA and PsA, Dr. Wells argued. “[I]f you don’t know, you can’t treat,” he said.
Some patients near remission may have radiographic progression even though disease activity measurements such as C-reactive protein (CRP) values do not show presence of active disease. In a study analyzing 1,184 patients with RA in the ASPIRE, ERA, Leflunomide, PREMIER and TEMPO trials, swollen joint count (SJC) was a better predictor of radiographic progression than CRP in patients near remission.
“[E]ven where you don’t see smoke, there still could be fire,” Dr. Wells said. “Some of these patients still progress and these are outliers, and the way they saw that [was] because they followed those patients along. If you don’t look, you don’t know.”
Radiographic progression can also be seen among nonswollen joints in patients with RA and PsA. In a study of 1,207 joints in 55 patients with RA and 352 joints in 18 patients with PsA, researchers in Austria found tenderness in nonswollen joints was associated with radiographic progression.
Despite having effective treatments in RA and PsA, “none of our therapies show that they’re able to prevent progression,” Dr. Wells said.
When it comes to hitting the treatment target in RA, some rheumatologists may think they can accomplish it without use of repeated radiographs. “I have a different perspective on that – that you really do indeed need to do the x-rays today and follow those x-rays along, especially if it’s going to change your treatment paradigm and what your treatment decision would be for the patient,” he said.
Counterpoint: Repeat radiographs aren’t helpful
Almost all rheumatologists would likely order an initial radiograph for their patients with RA or PsA, Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said in his presentation.
“If you see erosions when you start, chances are you’re going to be much more aggressive,” Dr. Fleischmann said. “So it is justification for early, more aggressive treatment of disease.”
In recent decades, radiographic progression in RA has decreased as more effective antirheumatic treatments have come into use, Dr. Fleischmann argued.
“We had x-ray progression in virtually everybody, and it was consistent no matter what we treated with, which was gold or penicillamine or any of the NSAIDs or sulfasalazine,” he said. “With methotrexate ... about 60% of patients actually have no x-ray progression, and that was a major change, and that’s one of the reasons why methotrexate has become the keystone of therapy. But even with methotrexate, [we] still had many patients who progressed.”
After the introduction of tumor necrosis factor inhibitors and other mechanisms in the late 1990s, “all of a sudden, you don’t see x-ray progression – mean x-ray progression – in a group of patients,” he noted.
Many rheumatologists now use a treat-to-target strategy, and if the patient achieves true clinical remission or sustained very low disease activity as measured by Boolean remission, Simple Disease Activity Index, or Clinical Disease Activity Index, they have “very little chance of radiographic progression and functional decline,” he said.
“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not where they want to be, where you want them to be; you’re going to make a change anyway,” Dr. Fleischmann explained. “The radiograph isn’t going to help you do that.”
If a patient is in sustained remission but a radiograph is ordered and shows disease progression, he questioned what the rheumatologist would do in that situation.
“Now the patient’s in, let’s say, a Boolean remission. They have no tender joints. They have no swollen joints ... their pain assessment is zero, their CRP is zero, and they do have some x-ray progression. Where are you going to change?” Dr. Fleischmann asked. “There’s no data that anything else would work. I don’t know what you would do. So, in conclusion, I would say you really don’t need to repeat an x-ray.”
AI reading x-rays?
Commenting on the point-counterpoint session, Arthur Kavanaugh, MD, professor of medicine at the University of California, San Diego, and director of RWCS, asked Dr. Fleischmann and Dr. Wells how they address the issue of how many radiologists seem to be unfamiliar with reading hand radiographs and RA progression.
Dr. Fleischmann said he was trained in how to read hand radiographs in medical school, but that training no longer appears to be occurring. “If you have a good bone radiologist, of which there are not a lot, you’re great. But if you don’t have a really good bone radiologist, it’s difficult,” he said.
Dr. Kavanaugh alluded to the advancement of artificial intelligence (AI) in radiology and posed the question of how both rheumatologists felt about AI reading and interpreting their radiographs. “If you could reliably submit x-rays and they would say what the Sharp score was and where the differences were, would that change anything?” he asked.
“I think having artificial intelligence read the x-ray or an MRI is really, really good. It’ll be better than the radiologists,” Dr. Fleischmann responded. “But I don’t think that you really need to repeat the x-ray. I mean, I really don’t think you need to repeat it. You need to treat the patient.”
Dr. Wells reported having financial relationships with numerous pharmaceutical companies. Dr. Fleischmann reported no relevant financial relationships.
Follow-up radiographs after an initial baseline reading in patients with rheumatoid arthritis or psoriatic arthritis may still show radiographic progression despite treatment with current therapies, but it’s unclear if they will affect treatment decisions between patients and doctors that may take place regardless of the radiographic information, according to arguments made for and against their usefulness in a point-counterpoint session at the 2023 Rheumatology Winter Clinical Symposium.
Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said that x-rays “reflect the history of joint pathology” and can get worse over time, correlating with disease activity and severity.
While RA does not yet have the “holy grail” of complete or true remission, Dr. Wells argued, the combination of clinical remission, laboratory remission, and imaging remission gets patients with RA close to the ideal when measured over time. “You need to continue to monitor these patients as you follow them along,” he said.
The BARFOT study, which evaluated 1,938 patients with early RA in two cohorts during 1992-1999 and again between 2000 and 2006, showed that more active treatments in the 2000s did not result in improvements in Health Assessment Questionnaire (HAQ) and pain scores, compared with patients treated in the 1990s. “You can see in some of those patients those scores do increase, and that even despite aggressive therapies that we had in 2006, you can still see some of those patients still have progression of the disease,” Dr. Wells explained. “How did they know? Because they looked.”
He also cited a study from researchers at the Mayo Clinic who examined 586 patients with RA that showed a higher prevalence of functional disability in patients with RA who also had radiographic changes, compared with patients without RA. “Radiographic changes correlate with disease severity and functional disability as well,” Dr. Wells said.
Just as prostate-specific antigen levels are used in prostate cancer screening and hemoglobin A1c is measured in diabetes management, radiographs should be used to track progression of disease in RA and PsA, Dr. Wells argued. “[I]f you don’t know, you can’t treat,” he said.
Some patients near remission may have radiographic progression even though disease activity measurements such as C-reactive protein (CRP) values do not show presence of active disease. In a study analyzing 1,184 patients with RA in the ASPIRE, ERA, Leflunomide, PREMIER and TEMPO trials, swollen joint count (SJC) was a better predictor of radiographic progression than CRP in patients near remission.
“[E]ven where you don’t see smoke, there still could be fire,” Dr. Wells said. “Some of these patients still progress and these are outliers, and the way they saw that [was] because they followed those patients along. If you don’t look, you don’t know.”
Radiographic progression can also be seen among nonswollen joints in patients with RA and PsA. In a study of 1,207 joints in 55 patients with RA and 352 joints in 18 patients with PsA, researchers in Austria found tenderness in nonswollen joints was associated with radiographic progression.
Despite having effective treatments in RA and PsA, “none of our therapies show that they’re able to prevent progression,” Dr. Wells said.
When it comes to hitting the treatment target in RA, some rheumatologists may think they can accomplish it without use of repeated radiographs. “I have a different perspective on that – that you really do indeed need to do the x-rays today and follow those x-rays along, especially if it’s going to change your treatment paradigm and what your treatment decision would be for the patient,” he said.
Counterpoint: Repeat radiographs aren’t helpful
Almost all rheumatologists would likely order an initial radiograph for their patients with RA or PsA, Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said in his presentation.
“If you see erosions when you start, chances are you’re going to be much more aggressive,” Dr. Fleischmann said. “So it is justification for early, more aggressive treatment of disease.”
In recent decades, radiographic progression in RA has decreased as more effective antirheumatic treatments have come into use, Dr. Fleischmann argued.
“We had x-ray progression in virtually everybody, and it was consistent no matter what we treated with, which was gold or penicillamine or any of the NSAIDs or sulfasalazine,” he said. “With methotrexate ... about 60% of patients actually have no x-ray progression, and that was a major change, and that’s one of the reasons why methotrexate has become the keystone of therapy. But even with methotrexate, [we] still had many patients who progressed.”
After the introduction of tumor necrosis factor inhibitors and other mechanisms in the late 1990s, “all of a sudden, you don’t see x-ray progression – mean x-ray progression – in a group of patients,” he noted.
Many rheumatologists now use a treat-to-target strategy, and if the patient achieves true clinical remission or sustained very low disease activity as measured by Boolean remission, Simple Disease Activity Index, or Clinical Disease Activity Index, they have “very little chance of radiographic progression and functional decline,” he said.
“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not where they want to be, where you want them to be; you’re going to make a change anyway,” Dr. Fleischmann explained. “The radiograph isn’t going to help you do that.”
If a patient is in sustained remission but a radiograph is ordered and shows disease progression, he questioned what the rheumatologist would do in that situation.
“Now the patient’s in, let’s say, a Boolean remission. They have no tender joints. They have no swollen joints ... their pain assessment is zero, their CRP is zero, and they do have some x-ray progression. Where are you going to change?” Dr. Fleischmann asked. “There’s no data that anything else would work. I don’t know what you would do. So, in conclusion, I would say you really don’t need to repeat an x-ray.”
AI reading x-rays?
Commenting on the point-counterpoint session, Arthur Kavanaugh, MD, professor of medicine at the University of California, San Diego, and director of RWCS, asked Dr. Fleischmann and Dr. Wells how they address the issue of how many radiologists seem to be unfamiliar with reading hand radiographs and RA progression.
Dr. Fleischmann said he was trained in how to read hand radiographs in medical school, but that training no longer appears to be occurring. “If you have a good bone radiologist, of which there are not a lot, you’re great. But if you don’t have a really good bone radiologist, it’s difficult,” he said.
Dr. Kavanaugh alluded to the advancement of artificial intelligence (AI) in radiology and posed the question of how both rheumatologists felt about AI reading and interpreting their radiographs. “If you could reliably submit x-rays and they would say what the Sharp score was and where the differences were, would that change anything?” he asked.
“I think having artificial intelligence read the x-ray or an MRI is really, really good. It’ll be better than the radiologists,” Dr. Fleischmann responded. “But I don’t think that you really need to repeat the x-ray. I mean, I really don’t think you need to repeat it. You need to treat the patient.”
Dr. Wells reported having financial relationships with numerous pharmaceutical companies. Dr. Fleischmann reported no relevant financial relationships.
Follow-up radiographs after an initial baseline reading in patients with rheumatoid arthritis or psoriatic arthritis may still show radiographic progression despite treatment with current therapies, but it’s unclear if they will affect treatment decisions between patients and doctors that may take place regardless of the radiographic information, according to arguments made for and against their usefulness in a point-counterpoint session at the 2023 Rheumatology Winter Clinical Symposium.
Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said that x-rays “reflect the history of joint pathology” and can get worse over time, correlating with disease activity and severity.
While RA does not yet have the “holy grail” of complete or true remission, Dr. Wells argued, the combination of clinical remission, laboratory remission, and imaging remission gets patients with RA close to the ideal when measured over time. “You need to continue to monitor these patients as you follow them along,” he said.
The BARFOT study, which evaluated 1,938 patients with early RA in two cohorts during 1992-1999 and again between 2000 and 2006, showed that more active treatments in the 2000s did not result in improvements in Health Assessment Questionnaire (HAQ) and pain scores, compared with patients treated in the 1990s. “You can see in some of those patients those scores do increase, and that even despite aggressive therapies that we had in 2006, you can still see some of those patients still have progression of the disease,” Dr. Wells explained. “How did they know? Because they looked.”
He also cited a study from researchers at the Mayo Clinic who examined 586 patients with RA that showed a higher prevalence of functional disability in patients with RA who also had radiographic changes, compared with patients without RA. “Radiographic changes correlate with disease severity and functional disability as well,” Dr. Wells said.
Just as prostate-specific antigen levels are used in prostate cancer screening and hemoglobin A1c is measured in diabetes management, radiographs should be used to track progression of disease in RA and PsA, Dr. Wells argued. “[I]f you don’t know, you can’t treat,” he said.
Some patients near remission may have radiographic progression even though disease activity measurements such as C-reactive protein (CRP) values do not show presence of active disease. In a study analyzing 1,184 patients with RA in the ASPIRE, ERA, Leflunomide, PREMIER and TEMPO trials, swollen joint count (SJC) was a better predictor of radiographic progression than CRP in patients near remission.
“[E]ven where you don’t see smoke, there still could be fire,” Dr. Wells said. “Some of these patients still progress and these are outliers, and the way they saw that [was] because they followed those patients along. If you don’t look, you don’t know.”
Radiographic progression can also be seen among nonswollen joints in patients with RA and PsA. In a study of 1,207 joints in 55 patients with RA and 352 joints in 18 patients with PsA, researchers in Austria found tenderness in nonswollen joints was associated with radiographic progression.
Despite having effective treatments in RA and PsA, “none of our therapies show that they’re able to prevent progression,” Dr. Wells said.
When it comes to hitting the treatment target in RA, some rheumatologists may think they can accomplish it without use of repeated radiographs. “I have a different perspective on that – that you really do indeed need to do the x-rays today and follow those x-rays along, especially if it’s going to change your treatment paradigm and what your treatment decision would be for the patient,” he said.
Counterpoint: Repeat radiographs aren’t helpful
Almost all rheumatologists would likely order an initial radiograph for their patients with RA or PsA, Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said in his presentation.
“If you see erosions when you start, chances are you’re going to be much more aggressive,” Dr. Fleischmann said. “So it is justification for early, more aggressive treatment of disease.”
In recent decades, radiographic progression in RA has decreased as more effective antirheumatic treatments have come into use, Dr. Fleischmann argued.
“We had x-ray progression in virtually everybody, and it was consistent no matter what we treated with, which was gold or penicillamine or any of the NSAIDs or sulfasalazine,” he said. “With methotrexate ... about 60% of patients actually have no x-ray progression, and that was a major change, and that’s one of the reasons why methotrexate has become the keystone of therapy. But even with methotrexate, [we] still had many patients who progressed.”
After the introduction of tumor necrosis factor inhibitors and other mechanisms in the late 1990s, “all of a sudden, you don’t see x-ray progression – mean x-ray progression – in a group of patients,” he noted.
Many rheumatologists now use a treat-to-target strategy, and if the patient achieves true clinical remission or sustained very low disease activity as measured by Boolean remission, Simple Disease Activity Index, or Clinical Disease Activity Index, they have “very little chance of radiographic progression and functional decline,” he said.
“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not where they want to be, where you want them to be; you’re going to make a change anyway,” Dr. Fleischmann explained. “The radiograph isn’t going to help you do that.”
If a patient is in sustained remission but a radiograph is ordered and shows disease progression, he questioned what the rheumatologist would do in that situation.
“Now the patient’s in, let’s say, a Boolean remission. They have no tender joints. They have no swollen joints ... their pain assessment is zero, their CRP is zero, and they do have some x-ray progression. Where are you going to change?” Dr. Fleischmann asked. “There’s no data that anything else would work. I don’t know what you would do. So, in conclusion, I would say you really don’t need to repeat an x-ray.”
AI reading x-rays?
Commenting on the point-counterpoint session, Arthur Kavanaugh, MD, professor of medicine at the University of California, San Diego, and director of RWCS, asked Dr. Fleischmann and Dr. Wells how they address the issue of how many radiologists seem to be unfamiliar with reading hand radiographs and RA progression.
Dr. Fleischmann said he was trained in how to read hand radiographs in medical school, but that training no longer appears to be occurring. “If you have a good bone radiologist, of which there are not a lot, you’re great. But if you don’t have a really good bone radiologist, it’s difficult,” he said.
Dr. Kavanaugh alluded to the advancement of artificial intelligence (AI) in radiology and posed the question of how both rheumatologists felt about AI reading and interpreting their radiographs. “If you could reliably submit x-rays and they would say what the Sharp score was and where the differences were, would that change anything?” he asked.
“I think having artificial intelligence read the x-ray or an MRI is really, really good. It’ll be better than the radiologists,” Dr. Fleischmann responded. “But I don’t think that you really need to repeat the x-ray. I mean, I really don’t think you need to repeat it. You need to treat the patient.”
Dr. Wells reported having financial relationships with numerous pharmaceutical companies. Dr. Fleischmann reported no relevant financial relationships.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>162248</fileName> <TBEID>0C0486BF.SIG</TBEID> <TBUniqueIdentifier>MD_0C0486BF</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname>RWCS 23 x-rays in RA PsA</storyname> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20230216T135810</QCDate> <firstPublished>20230216T140715</firstPublished> <LastPublished>20230216T140716</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20230216T140715</CMSDate> <articleSource>FROM RWCS 2023</articleSource> <facebookInfo/> <meetingNumber>4660-23</meetingNumber> <byline>Jeff Craven</byline> <bylineText>JEFF CRAVEN</bylineText> <bylineFull>JEFF CRAVEN</bylineFull> <bylineTitleText>MDedge News</bylineTitleText> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>Follow-up radiographs after an initial baseline reading in patients with rheumatoid arthritis or psoriatic arthritis may still show radiographic progression des</metaDescription> <articlePDF/> <teaserImage>274246</teaserImage> <teaser>“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not where they want to be, where you want them to be; you’re going to make a change anyway,” Dr. Roy Fleischmann said. “The radiograph isn’t going to help you do that.” </teaser> <title>Are repeat radiographs necessary in rheumatoid and psoriatic arthritis?</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>rn</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>fp</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">26</term> <term>21</term> <term>15</term> </publications> <sections> <term canonical="true">53</term> <term>39313</term> </sections> <topics> <term canonical="true">289</term> <term>282</term> <term>290</term> </topics> <links> <link> <itemClass qcode="ninat:picture"/> <altRep contenttype="image/jpeg">images/2400f650.jpg</altRep> <description role="drol:caption"/> <description role="drol:credit">BSIP/UIG/GettyImages</description> </link> <link> <itemClass qcode="ninat:picture"/> <altRep contenttype="image/jpeg">images/240110d5.jpg</altRep> <description role="drol:caption">Dr. Alvin Wells</description> <description role="drol:credit"/> </link> <link> <itemClass qcode="ninat:picture"/> <altRep contenttype="image/jpeg">images/24011330.jpg</altRep> <description role="drol:caption">Dr. Roy M. Fleischmann</description> <description role="drol:credit"/> </link> </links> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Are repeat radiographs necessary in rheumatoid and psoriatic arthritis?</title> <deck/> </itemMeta> <itemContent> <p>Follow-up radiographs after an initial baseline reading in patients with rheumatoid arthritis or psoriatic arthritis may still show radiographic progression despite treatment with current therapies, but it’s unclear if they will affect treatment decisions between patients and doctors that may take place regardless of the radiographic information, according to arguments made for and against their usefulness in a point-counterpoint session at the 2023 Rheumatology Winter Clinical Symposium.</p> <p>Alvin Wells, MD, PhD, director of the department of rheumatology at Advocate Aurora Health in Franklin, Wisc., said that x-rays “reflect the history of joint pathology” and can get worse over time, correlating with disease activity and severity.<br/><br/>[[{"fid":"274246","view_mode":"medstat_image_flush_left","fields":{"format":"medstat_image_flush_left","field_file_image_alt_text[und][0][value]":"Rheumatology consultation between provider and older patient","field_file_image_credit[und][0][value]":"BSIP/UIG/GettyImages","field_file_image_caption[und][0][value]":""},"type":"media","attributes":{"class":"media-element file-medstat_image_flush_left"}}]]While RA does not yet have the “holy grail” of complete or true remission, Dr. Wells argued, the combination of clinical remission, laboratory remission, and imaging remission gets patients with RA close to the ideal when measured over time. “You need to continue to monitor these patients as you follow them along,” he said.<br/><br/>The <span class="Hyperlink"><a href="https://www.jrheum.org/content/44/6/723">BARFOT study</a></span>, which evaluated 1,938 patients with early RA in two cohorts during 1992-1999 and again between 2000 and 2006, showed that more active treatments in the 2000s did not result in improvements in Health Assessment Questionnaire (HAQ) and pain scores, compared with patients treated in the 1990s. “You can see in some of those patients those scores do increase, and that even despite aggressive therapies that we had in 2006, you can still see some of those patients still have progression of the disease,” Dr. Wells explained. “How did they know? Because they looked.”<br/><br/>[[{"fid":"288874","view_mode":"medstat_image_flush_right","fields":{"format":"medstat_image_flush_right","field_file_image_alt_text[und][0][value]":"Dr. Alvin Wells, director of the Department of Rheumatology at Advocate Aurora Medical Group, Franklin, Wisconsin","field_file_image_credit[und][0][value]":"","field_file_image_caption[und][0][value]":"Dr. Alvin Wells"},"type":"media","attributes":{"class":"media-element file-medstat_image_flush_right"}}]]He also cited a <span class="Hyperlink"><a href="https://www.mayoclinicproceedings.org/article/S0025-6196(19)30005-9/fulltext">study from researchers at the Mayo Clinic</a></span> who examined 586 patients with RA that showed a higher prevalence of functional disability in patients with RA who also had radiographic changes, compared with patients without RA. “Radiographic changes correlate with disease severity and functional disability as well,” Dr. Wells said.<br/><br/>Just as prostate-specific antigen levels are used in prostate cancer screening and hemoglobin A1c is measured in diabetes management, radiographs should be used to track progression of disease in RA and PsA, Dr. Wells argued. “[I]f you don’t know, you can’t treat,” he said.<br/><br/>Some patients near remission may have radiographic progression even though disease activity measurements such as C-reactive protein (CRP) values do not show presence of active disease. In a <span class="Hyperlink"><a href="https://ard.bmj.com/content/70/11/1975">study analyzing 1,184 patients with RA</a></span> in the ASPIRE, ERA, Leflunomide, PREMIER and TEMPO trials, swollen joint count (SJC) was a better predictor of radiographic progression than CRP in patients near remission.<br/><br/>“[E]ven where you don’t see smoke, there still could be fire,” Dr. Wells said. “Some of these patients still progress and these are outliers, and the way they saw that [was] because they followed those patients along. If you don’t look, you don’t know.”<br/><br/>Radiographic progression can also be seen among nonswollen joints in patients with RA and PsA. In a study of 1,207 joints in 55 patients with RA and 352 joints in 18 patients with PsA, <span class="Hyperlink"><a href="https://ard.bmj.com/content/82/3/344">researchers in Austria</a></span> found tenderness in nonswollen joints was associated with radiographic progression.<br/><br/>Despite having effective treatments in RA and PsA, “none of our therapies show that they’re able to prevent progression,” Dr. Wells said. <br/><br/>When it comes to hitting the treatment target in RA, some rheumatologists may think they can accomplish it without use of repeated radiographs. “I have a different perspective on that – that you really do indeed need to do the x-rays today and follow those x-rays along, especially if it’s going to change your treatment paradigm and what your treatment decision would be for the patient,” he said.<br/><br/></p> <h2>Counterpoint: Repeat radiographs aren’t helpful</h2> <p>Almost all rheumatologists would likely order an initial radiograph for their patients with RA or PsA, Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas, said in his presentation.</p> <p>“If you see erosions when you start, chances are you’re going to be much more aggressive,” Dr. Fleischmann said. “So it is justification for early, more aggressive treatment of disease.” <br/><br/>In recent decades, <span class="Hyperlink"><a href="https://ard.bmj.com/content/65/9/1192">radiographic progression in RA has decreased</a></span> as more effective antirheumatic treatments have come into use, Dr. Fleischmann argued.<br/><br/>[[{"fid":"289698","view_mode":"medstat_image_flush_right","fields":{"format":"medstat_image_flush_right","field_file_image_alt_text[und][0][value]":"Dr. Roy M. Fleischmann, clinical professor of medicine at the University of Texas and codirector of the Metroplex Clinical Research Center, both in Dallas","field_file_image_credit[und][0][value]":"","field_file_image_caption[und][0][value]":"Dr. Roy M. Fleischmann"},"type":"media","attributes":{"class":"media-element file-medstat_image_flush_right"}}]]“We had x-ray progression in virtually everybody, and it was consistent no matter what we treated with, which was gold or penicillamine or any of the NSAIDs or sulfasalazine,” he said. “With methotrexate ... about 60% of patients actually have no x-ray progression, and that was a major change, and that’s one of the reasons why methotrexate has become the keystone of therapy. But even with methotrexate, [we] still had many patients who progressed.”<br/><br/>After the introduction of tumor necrosis factor inhibitors and other mechanisms in the late 1990s, “all of a sudden, you don’t see x-ray progression – mean x-ray progression – in a group of patients,” he noted.<br/><br/>Many rheumatologists now use a treat-to-target strategy, and if the patient achieves true clinical remission or sustained very low disease activity as measured by Boolean remission, Simple Disease Activity Index, or Clinical Disease Activity Index, they have “very little chance of radiographic progression and functional decline,” he said. <br/><br/>“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not where they want to be, where you want them to be; you’re going to make a change anyway,” Dr. Fleischmann explained. “The radiograph isn’t going to help you do that.” <br/><br/>If a patient is in sustained remission but a radiograph is ordered and shows disease progression, he questioned what the rheumatologist would do in that situation.<br/><br/>“Now the patient’s in, let’s say, a Boolean remission. They have no tender joints. They have no swollen joints ... their pain assessment is zero, their CRP is zero, and they do have some x-ray progression. Where are you going to change?” Dr. Fleischmann asked. “There’s no data that anything else would work. I don’t know what you would do. So, in conclusion, I would say you really don’t need to repeat an x-ray.”<br/><br/></p> <h2>AI reading x-rays?</h2> <p>Commenting on the point-counterpoint session, Arthur Kavanaugh, MD, professor of medicine at the University of California, San Diego, and director of RWCS, asked Dr. Fleischmann and Dr. Wells how they address the issue of how many radiologists seem to be unfamiliar with reading hand radiographs and RA progression. </p> <p>Dr. Fleischmann said he was trained in how to read hand radiographs in medical school, but that training no longer appears to be occurring. “If you have a good bone radiologist, of which there are not a lot, you’re great. But if you don’t have a really good bone radiologist, it’s difficult,” he said.<br/><br/>Dr. Kavanaugh alluded to the advancement of artificial intelligence (AI) in radiology and posed the question of how both rheumatologists felt about AI reading and interpreting their radiographs. “If you could reliably submit x-rays and they would say what the Sharp score was and where the differences were, would that change anything?” he asked.<br/><br/>“I think having artificial intelligence read the x-ray or an MRI is really, really good. It’ll be better than the radiologists,” Dr. Fleischmann responded. “But I don’t think that you really need to repeat the x-ray. I mean, I really don’t think you need to repeat it. You need to treat the patient.”<br/><br/>Dr. Wells reported having financial relationships with numerous pharmaceutical companies. Dr. Fleischmann reported no relevant financial relationships.</p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>
FROM RWCS 2023
